[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"fda-warning-letters-search:[\"Cook Inc.\",\"\",\"\",\"\",\"\",1]":3,"fda-latest-sync-dates":241},{"warningLetters":4,"total":240},[5,32,52,66,83,108,132,154,166,178,199,220],{"id":6,"raw":7,"subject":12,"body_html":14,"body_text":15,"firm_name":16,"letter_id":17,"created_at":18,"fei_number":19,"letter_url":20,"updated_at":21,"action_type":22,"case_status":23,"posted_date":24,"marcs_cms_no":25,"product_type":26,"closeout_date":19,"issuing_office":27,"recipient_name":28,"body_fetched_at":29,"delivery_method":30,"recipient_title":19,"reference_number":19,"action_taken_date":31,"medical_device_id":19,"response_letter_date":19},1448,[8,9,10,11,12,13,13,13],"\u003Ctime datetime=\"2024-05-21T13:20:00Z\">05\u002F21\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-04-22T04:00:00Z\">04\u002F22\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcookies-n-milk-llc-672621-04222024\">Cookies-n-Milk, LLC\u003C\u002Fa>"," Division of Human and Animal Food West III Compliance Branch (HAFW3-CB)","CGMP\u002FPackaging\u002FMisbranded","","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Overnight Delivery\n                                                                                                                                                                                                                                                                                                                                                                                      \u003Cbr>Return Receipt Requested\n                                                                          \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Tyler F.B. Spragg\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Vice President and General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cookies-n-Milk, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>181 Industrial Blvd.\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>McKinney\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>75069\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food West III Compliance Branch (HAFW3-CB)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>April 22, 2024\u003C\u002Fp>\n\n\u003Cp>CMS # 672621\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Spragg:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) cookie dough manufacturing facility located at 181 Industrial Blvd., McKinney, TX 75069 on October 3 -19, 2023. The inspection was initiated as a result of a Class 1 recall of your Cookies-n-Milk brand Chocolate Chip Edible Cookie Dough because of using incorrect packaging, which resulted in undeclared peanut allergen in the product, as containers of Chocolate Chip Edible Cookie Dough&nbsp;which do not declare the allergen peanuts were filled with Peanut Butter Edible Cookie Dough which contain peanuts. During our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-based Preventive Controls for Human Food regulation (CGMP and PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).&nbsp;\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings, we have determined that the RTE Peanut Butter Cup Edible Cookie Dough manufactured in your facility is misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product labels did not declare a major food allergen (peanuts). The RTE Edible Cookie Dough Peanut Butter Cup is also misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare all the common or usual names of each ingredient used. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act (21 U.S.C. § 331(uu)). You may find the Act and further information about the CGMP &amp; PC rule through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>At the conclusion of the inspection, the FDA issued a Form FDA 483 (FDA-483), Inspectional Observations. FDA received your written response, dated November 9, 2023, describing corrective actions taken and planned by your firm. After reviewing the inspectional findings and response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We also address your response below.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Hazard Analysis and Risk Based Preventive Controls (21 CFR Part 117, Subpart C)\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>1.&nbsp;&nbsp; &nbsp;Your hazard analysis did not identify and evaluate all known or reasonably foreseeable hazards to determine whether there are hazards requiring a preventive control for your RTE Edible Cookie Dough products, as required by 21 CFR 117.130(a)(1). Specifically:&nbsp;\u003C\u002Fp>\n\n\u003Cp>a.&nbsp;&nbsp; &nbsp;You did not identify and evaluate undeclared allergens due to incorrect labeling as a known or reasonably foreseeable hazard to determine whether they require a preventive control at the packaging\u002Flabeling step. &nbsp;Your facility manufactures, packages, and distributes RTE Edible Cookie Dough products with and without peanuts, in addition to other allergens (soy, milk, wheat). Therefore, allergens are a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify allergens as a hazard requiring a preventive control at the packaging\u002Flabeling step. Food allergen controls include procedures, practices, and processes employed for labeling to ensure that all food allergens required to be stated are included on the label (see 21 CFR 117.135(c)(2)(ii)).&nbsp;\u003C\u002Fp>\n\n\u003Cp>We note that your hazard analysis identifies undeclared allergens as a hazard requiring a preventive control at the “Receiving of Packaging Materials” step. Your allergen controls at this receiving step include “Pre-printed label review of ingredient statements and “contains:xxx” allergen(s) statement.” However, you do not monitor or verify that these preprinted labels are applied to the correct product during production (such as at the packaging\u002Flabeling step). Your firm’s investigation indicated that a lack of packaging controls resulted in containers of “Chocolate Chip Edible Cookie Dough,” which do not declare the allergen peanuts on the product label, being filled with Peanut Butter Edible Cookie Dough which contain peanuts. As a consequence, on September 27, 2023, your facility recalled 2,354 cases of 6oz cups of Cookies-n-Milk brand \"Chocolate Chip Edible Cookie Dough\" (lot # 3240), due to undeclared peanuts on the product label.&nbsp;\u003C\u002Fp>\n\n\u003Cp>b.&nbsp;&nbsp; &nbsp;You did not identify and evaluate mycotoxins as a known or reasonably foreseeable hazard to determine whether they require a preventive control. Your facility manufactures RTE edible cookie dough products containing peanut butter, which has been associated with mycotoxins such as aflatoxin. &nbsp;A knowledgeable person manufacturing\u002F processing food in your circumstances would identify mycotoxins as a hazard requiring a preventive control in peanut butter and peanut butter-containing ingredients. Further, a facility that identifies raw materials and other ingredients that require a supply-chain-applied control, such as mycotoxins, must establish and implement a risk-based supply-chain program for those raw materials and ingredients (see 21 CFR 117.405(a)(1)). The supply-chain program must include using approved suppliers and conducting supplier verification activities (see 21 CFR 117.410). You do not conduct supplier verification activities for mycotoxins in peanut butter and peanut butter-containing ingredients. &nbsp; &nbsp;\u003C\u002Fp>\n\n\u003Cp>Your November 9, 2023 response included root cause analysis and corrective action reports; a photograph of the recalled product (i.e., Peanut Butter Edible Cookie Dough in Chocolate Chip Edible Cookie Dough container); a certificate of analysis for \u003Cstrong>(b)(4)\u003C\u002Fstrong> RTE wheat flour which includes a statement for mycotoxins; and part of a revised raw ingredient hazard analysis that identifies the mycotoxin hazard as a significant hazard for the flour ingredient. Your response stated that “The Edible Cookie Dough hazard analysis will be revised to identify undeclared allergens due to mislabeling\u002Fpackaging as a potential hazard with controls at packaging implemented with monitoring and verification procedures defined” and “The Edible Cookie Dough hazard analysis will be revised to identify Mycotoxins as a potential hazard for Wheat Flour and Peanut Butter with controls at the supplier level implemented with monitoring and verification procedures defined.” However, the response did not contain sufficient supporting documentation for FDA to adequately evaluate your corrective actions. In addition, the response did not include a complete updated hazard analysis (to identify mycotoxins as a hazard requiring a preventive control for peanut butter and peanut butter-containing ingredients, and to identify undeclared allergens as a hazard requiring a preventive control at the packaging\u002Flabeling step) or revised food safety procedures. &nbsp;\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranding\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your Cookies-n-Milk brand RTE Peanut Butter Cup Edible Cookie Dough, lot 3240, is misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product label fails to declare a major food allergen (peanuts). Specifically, you manufactured Cookies-n-Milk RTE Peanut Butter Cup Edible Cookie Dough, lot 3240 (containing allergens: soy, milk, wheat, and peanut) and placed this product into the preprinted labeled cup for the Cookies-n-Milk RTE Chocolate Chip Edible Cookie Dough (containing soy, milk, wheat). The product was placed in incorrectly labeled cups, which did not list peanut on the label. Under section 201(qq) of the Act [21 U.S.C. § 321(qq)], peanuts are considered a “major food allergen.” A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;The word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., “Peanuts”), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\u003C\u002Fp>\n\n\u003Cp>Your Cookies-n-Milk brand Peanut Butter Cup Edible Cookie Dough Peanut product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare all the common or usual names of each ingredient used as required by 21 CFR 101.4. Your product is manufactured using milk powder (an allergen) and baking soda; however, the product label fails to declare these ingredients in the ingredient statement although those ingredients are added, as per the list of ingredients in the product formulation sheet. &nbsp;Furthermore, you directly add salt as an ingredient to your Cookies-n-Milk brand Peanut Butter Cup Edible Cookie Dough product; however, salt is not declared as an added ingredient separate from the sub ingredients of the margarine and peanut butter chocolate cups.\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Additional Comments:\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We also offer the following comments regarding your Cookies-n-Milk RTE Peanut Butter Cup Edible Cookie Dough and your Cookies-n-Milk RTE Chocolate Chip Edible Cookie Dough product labels:\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;In accordance with 21 CFR 101.5(d), the statement of the place of business shall include the street address, city, state, and zip code; however, the street address may be omitted if it is shown in a current city directory or telephone directory.\u003C\u002Fp>\n\n\u003Cp>•&nbsp;&nbsp; &nbsp;We note that the labels are missing the words “Net Weight” in accordance with 21 CFR 101.7(j)(3).\u003C\u002Fp>\n\n\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at the following email: dana.lewis@fda.hhs.gov or you may mail a hard copy, addressed to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any further questions, please contact me at&nbsp;(214) 253-5200 or by email.\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003Cbr>\nFor:&nbsp;&nbsp; &nbsp;Edmundo Garcia, Jr.\u003Cbr>\nProgram Division Director HAFW3 Dallas District Director\u003C\u002Fp>\n\n\u003Cp>\u003Cbr>\nCc: &nbsp;Texas Department of State Health Services\u003Cbr>\n&nbsp; &nbsp; &nbsp;Lori Woznicki, Food and Drug Inspections Branch Manager Division of Regulatory Services\u003Cbr>\n&nbsp; &nbsp; &nbsp;Texas Department of State Health Services lori.woznicki@dshs.texas.gov\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Overnight Delivery\n\nReturn Receipt Requested\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nTyler F.B. Spragg\n\nRecipient Title\n\nVice President and General Manager\n\nCookies-n-Milk, LLC\n\n181 Industrial Blvd.\n\nMcKinney, TX 75069\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food West III Compliance Branch (HAFW3-CB)\n\nUnited States\n\nWARNING LETTER\n\nApril 22, 2024\n\nCMS # 672621\n\nDear Mr. Spragg:\n\nThe United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) cookie dough manufacturing facility located at 181 Industrial Blvd., McKinney, TX 75069 on October 3 -19, 2023. The inspection was initiated as a result of a Class 1 recall of your Cookies-n-Milk brand Chocolate Chip Edible Cookie Dough because of using incorrect packaging, which resulted in undeclared peanut allergen in the product, as containers of Chocolate Chip Edible Cookie Dough which do not declare the allergen peanuts were filled with Peanut Butter Edible Cookie Dough which contain peanuts. During our inspection, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-based Preventive Controls for Human Food regulation (CGMP and PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117).\n\nBased on FDA’s inspectional findings, we have determined that the RTE Peanut Butter Cup Edible Cookie Dough manufactured in your facility is misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product labels did not declare a major food allergen (peanuts). The RTE Edible Cookie Dough Peanut Butter Cup is also misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare all the common or usual names of each ingredient used. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act (21 U.S.C. § 331(uu)). You may find the Act and further information about the CGMP & PC rule through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nAt the conclusion of the inspection, the FDA issued a Form FDA 483 (FDA-483), Inspectional Observations. FDA received your written response, dated November 9, 2023, describing corrective actions taken and planned by your firm. After reviewing the inspectional findings and response that your firm provided, we are issuing this letter to advise you of FDA’s concerns and provide detailed information describing the findings at your facility. We also address your response below.\n\nYour significant violations are as follows:\n\nHazard Analysis and Risk Based Preventive Controls (21 CFR Part 117, Subpart C)\n\n1. Your hazard analysis did not identify and evaluate all known or reasonably foreseeable hazards to determine whether there are hazards requiring a preventive control for your RTE Edible Cookie Dough products, as required by 21 CFR 117.130(a)(1). Specifically:\n\na. You did not identify and evaluate undeclared allergens due to incorrect labeling as a known or reasonably foreseeable hazard to determine whether they require a preventive control at the packaging\u002Flabeling step. Your facility manufactures, packages, and distributes RTE Edible Cookie Dough products with and without peanuts, in addition to other allergens (soy, milk, wheat). Therefore, allergens are a known or reasonably foreseeable hazard. A knowledgeable person manufacturing\u002Fprocessing food in your circumstances would identify allergens as a hazard requiring a preventive control at the packaging\u002Flabeling step. Food allergen controls include procedures, practices, and processes employed for labeling to ensure that all food allergens required to be stated are included on the label (see 21 CFR 117.135(c)(2)(ii)).\n\nWe note that your hazard analysis identifies undeclared allergens as a hazard requiring a preventive control at the “Receiving of Packaging Materials” step. Your allergen controls at this receiving step include “Pre-printed label review of ingredient statements and “contains:xxx” allergen(s) statement.” However, you do not monitor or verify that these preprinted labels are applied to the correct product during production (such as at the packaging\u002Flabeling step). Your firm’s investigation indicated that a lack of packaging controls resulted in containers of “Chocolate Chip Edible Cookie Dough,” which do not declare the allergen peanuts on the product label, being filled with Peanut Butter Edible Cookie Dough which contain peanuts. As a consequence, on September 27, 2023, your facility recalled 2,354 cases of 6oz cups of Cookies-n-Milk brand \"Chocolate Chip Edible Cookie Dough\" (lot # 3240), due to undeclared peanuts on the product label.\n\nb. You did not identify and evaluate mycotoxins as a known or reasonably foreseeable hazard to determine whether they require a preventive control. Your facility manufactures RTE edible cookie dough products containing peanut butter, which has been associated with mycotoxins such as aflatoxin. A knowledgeable person manufacturing\u002F processing food in your circumstances would identify mycotoxins as a hazard requiring a preventive control in peanut butter and peanut butter-containing ingredients. Further, a facility that identifies raw materials and other ingredients that require a supply-chain-applied control, such as mycotoxins, must establish and implement a risk-based supply-chain program for those raw materials and ingredients (see 21 CFR 117.405(a)(1)). The supply-chain program must include using approved suppliers and conducting supplier verification activities (see 21 CFR 117.410). You do not conduct supplier verification activities for mycotoxins in peanut butter and peanut butter-containing ingredients.\n\nYour November 9, 2023 response included root cause analysis and corrective action reports; a photograph of the recalled product (i.e., Peanut Butter Edible Cookie Dough in Chocolate Chip Edible Cookie Dough container); a certificate of analysis for (b)(4) RTE wheat flour which includes a statement for mycotoxins; and part of a revised raw ingredient hazard analysis that identifies the mycotoxin hazard as a significant hazard for the flour ingredient. Your response stated that “The Edible Cookie Dough hazard analysis will be revised to identify undeclared allergens due to mislabeling\u002Fpackaging as a potential hazard with controls at packaging implemented with monitoring and verification procedures defined” and “The Edible Cookie Dough hazard analysis will be revised to identify Mycotoxins as a potential hazard for Wheat Flour and Peanut Butter with controls at the supplier level implemented with monitoring and verification procedures defined.” However, the response did not contain sufficient supporting documentation for FDA to adequately evaluate your corrective actions. In addition, the response did not include a complete updated hazard analysis (to identify mycotoxins as a hazard requiring a preventive control for peanut butter and peanut butter-containing ingredients, and to identify undeclared allergens as a hazard requiring a preventive control at the packaging\u002Flabeling step) or revised food safety procedures.\n\nMisbranding\n\nYour Cookies-n-Milk brand RTE Peanut Butter Cup Edible Cookie Dough, lot 3240, is misbranded within the meaning of section 403(w) of the Act [21 U.S.C. § 343(w)], in that the finished product label fails to declare a major food allergen (peanuts). Specifically, you manufactured Cookies-n-Milk RTE Peanut Butter Cup Edible Cookie Dough, lot 3240 (containing allergens: soy, milk, wheat, and peanut) and placed this product into the preprinted labeled cup for the Cookies-n-Milk RTE Chocolate Chip Edible Cookie Dough (containing soy, milk, wheat). The product was placed in incorrectly labeled cups, which did not list peanut on the label. Under section 201(qq) of the Act [21 U.S.C. § 321(qq)], peanuts are considered a “major food allergen.” A food is misbranded under section 403(w) of the Act if it is not a raw agricultural commodity and it is, or it contains, an ingredient that bears or contains, a major food allergen, unless either:\n\n• The word “Contains” followed by the name of the food source from which the major food allergen is derived, is printed immediately after or adjacent to the list of ingredients, section 403(w)(1)(A) of the Act [21 U.S.C. § 343(w)(1)(A)]; or\n\n• The common or usual name of the major food allergen in the list of ingredients is followed in parentheses by the name of the food source from which the major food allergen is derived (e.g., “Peanuts”), except the name of the food source is not required when either the common or usual name of the ingredient uses the name of the food source or the name of the food source appears elsewhere in the ingredient list (unless the name of the food source that appears elsewhere in the ingredient list appears as part of the name of an ingredient that is not a major food allergen), section 403(w)(1)(B) of the Act [21 U.S.C. § 343(w)(1)(B)].\n\nYour Cookies-n-Milk brand Peanut Butter Cup Edible Cookie Dough Peanut product is misbranded within the meaning of section 403(i)(2) of the Act [21 U.S.C. § 343(i)(2)] in that the product label fails to declare all the common or usual names of each ingredient used as required by 21 CFR 101.4. Your product is manufactured using milk powder (an allergen) and baking soda; however, the product label fails to declare these ingredients in the ingredient statement although those ingredients are added, as per the list of ingredients in the product formulation sheet. Furthermore, you directly add salt as an ingredient to your Cookies-n-Milk brand Peanut Butter Cup Edible Cookie Dough product; however, salt is not declared as an added ingredient separate from the sub ingredients of the margarine and peanut butter chocolate cups.\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may result in legal action including, without limitation, seizure and injunction.\n\nAdditional Comments:\n\nWe also offer the following comments regarding your Cookies-n-Milk RTE Peanut Butter Cup Edible Cookie Dough and your Cookies-n-Milk RTE Chocolate Chip Edible Cookie Dough product labels:\n\n• In accordance with 21 CFR 101.5(d), the statement of the place of business shall include the street address, city, state, and zip code; however, the street address may be omitted if it is shown in a current city directory or telephone directory.\n\n• We note that the labels are missing the words “Net Weight” in accordance with 21 CFR 101.7(j)(3).\n\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nYour response should be sent to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at the following email: dana.lewis@fda.hhs.gov or you may mail a hard copy, addressed to Dana Lewis, Compliance Officer, U.S. Food and Drug Administration at 1201 Main Street, Suite 7200, Dallas, TX 75202. If you have any further questions, please contact me at (214) 253-5200 or by email.\n\nSincerely,\n\n\u002FS\u002F\n\nFor: Edmundo Garcia, Jr.\n\nProgram Division Director HAFW3 Dallas District Director\n\nCc: Texas Department of State Health Services\n\nLori Woznicki, Food and Drug Inspections Branch Manager Division of Regulatory Services\n\nTexas Department of State Health Services lori.woznicki@dshs.texas.gov","Cookies-n-Milk, LLC","cookies-n-milk-llc-672621-04222024","2026-08-18T06:42:28.856152+00:00",null,"https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcookies-n-milk-llc-672621-04222024","2026-10-26T08:08:17.701953+00:00","Warning Letter","Issued","2024-05-21","672621","Food & Beverages","Division of Human and Animal Food West III Compliance Branch (HAFW3-CB)","Tyler F.B. Spragg","2026-08-20T00:04:29.752+00:00","Via Overnight Delivery Return Receipt Requested","2024-04-22",{"id":33,"raw":34,"subject":38,"body_html":39,"body_text":40,"firm_name":41,"letter_id":42,"created_at":43,"fei_number":19,"letter_url":44,"updated_at":45,"action_type":22,"case_status":23,"posted_date":46,"marcs_cms_no":47,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":49,"delivery_method":50,"recipient_title":19,"reference_number":51,"action_taken_date":46,"medical_device_id":19,"response_letter_date":19},557,[35,35,36,37,38,13,13,13],"\u003Ctime datetime=\"2025-10-02T04:00:00Z\">10\u002F02\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcool-vape-llc-714194-10022025\">Cool Vape LLC\u003C\u002Fa>","Center for Tobacco Products","Family Smoking Prevention and Tobacco Control Act\u002FAdulterated\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501283\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Cool Vape LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>904 South 5th Street, Suite 102\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sanger\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76266\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 2, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Cool Vape LLC sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Noms 100 Watermelon Blackberry Plum 100ML 3MG\u002FML.\u003C\u002Fp>\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501283, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501283\n\nProduct:\n\nTobacco\n\nRecipient:\n\nCool Vape LLC\n\n904 South 5th Street, Suite 102\n\nSanger, TX 76266\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nOctober 2, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Cool Vape LLC sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Noms 100 Watermelon Blackberry Plum 100ML 3MG\u002FML.\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501283, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","Cool Vape LLC","cool-vape-llc-714194-10022025","2026-08-18T06:42:28.676509+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcool-vape-llc-714194-10022025","2026-10-26T08:08:17.801835+00:00","2025-10-02","714194","Tobacco","2026-08-19T16:15:35.031+00:00","VIA UPS and Electronic Mail","ER2501283",{"id":53,"raw":54,"subject":38,"body_html":57,"body_text":58,"firm_name":41,"letter_id":59,"created_at":18,"fei_number":19,"letter_url":60,"updated_at":61,"action_type":22,"case_status":23,"posted_date":62,"marcs_cms_no":63,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":19,"body_fetched_at":64,"delivery_method":50,"recipient_title":19,"reference_number":65,"action_taken_date":62,"medical_device_id":19,"response_letter_date":19},1016,[55,55,56,37,38,13,13,13],"\u003Ctime datetime=\"2025-03-13T04:00:00Z\">03\u002F13\u002F2025\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcool-vape-llc-700168-03132025\">Cool Vape LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>ER2501118\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\u003C\u002Fdd>\n                    \n            \u003Cdd>Cool Vape LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>904 South 5th Street, Suite 102\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sanger\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76266\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>904 South 5th Street, Suite 102\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Sanger\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>76266\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 13, 2025\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>To Whom It May Concern:\u003C\u002Fp>\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Cool Vape LLC manufactures, sells and\u002For distributes e-liquid products to customers in the United States.\u003C\u002Fp>\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please be aware that, on March 15, 2022, the President signed legislation to amend the FD&amp;C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&amp;C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&amp;C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\u003C\u002Fp>\u003Cp>Generally, to be legally marketed in the United States, the FD&amp;C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\u003Cp>\u003Cstrong>New Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Blueberry.\u003C\u002Fp>\u003Cp>The tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&amp;C Act.\u003C\u002Fp>\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>FDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\u003C\u002Fp>\u003Cp>For a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\u003C\u002Fp>\u003Cp>It is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to address any violations of the FD&amp;C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that these products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\u003Cp>Please note your reference number, ER2501118, in your response and direct your response to the following address:\u003C\u002Fp>\u003Cp>DEM-WL Response, Office of Compliance and Enforcement&nbsp;&nbsp;\u003Cbr>FDA Center for Tobacco Products&nbsp;&nbsp;\u003Cbr>c\u002Fo Document Control Center&nbsp;&nbsp;\u003Cbr>Building 71, Room G335&nbsp;&nbsp;\u003Cbr>10903 New Hampshire Avenue&nbsp;&nbsp;\u003Cbr>Silver Spring, MD 20993-0002&nbsp;\u003C\u002Fp>\u003Cp>If you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>John E. Verbeten\u003Cbr>Director\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Center for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nReference #:\n\nER2501118\n\nProduct:\n\nTobacco\n\nRecipient:\n\nCool Vape LLC\n\n904 South 5th Street, Suite 102\n\nSanger, TX 76266\n\nUnited States\n\nIssuing Office:\n\nCenter for Tobacco Products\n\n904 South 5th Street, Suite 102\n\nSanger, TX 76266\n\nUnited States\n\nMarch 13, 2025\nWARNING LETTER\nTo Whom It May Concern:\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) recently reviewed our inspection records and determined that Cool Vape LLC manufactures, sells and\u002For distributes e-liquid products to customers in the United States.\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco or contain nicotine from any source and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1, and are required to be in compliance with the requirements in the FD&C Act.\nPlease be aware that, on March 15, 2022, the President signed legislation to amend the FD&C Act to extend FDA’s jurisdiction to products “containing nicotine from any source,” not just nicotine derived from tobacco. See Consolidated Appropriations Act, 2022, Public Law 117-103, Division P, Title I, Subtitle B. Specifically, this legislation expanded the definition of “tobacco product” under section 201(rr) of the FD&C Act (21 U.S.C. § 321(rr)) to include products containing nicotine from any source. Tobacco products, including e-liquid products, containing nicotine from any source, must be in compliance with the FD&C Act and its implementing regulations. For more information, please see https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fctp-newsroom\u002Frequirements-products-made-non-tobacco-nicotine-take-effect-april-14.\nGenerally, to be legally marketed in the United States, the FD&C Act requires “new tobacco products” to have a premarket authorization order in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\nNew Tobacco Products Without Required Marketing Authorization Are Adulterated and Misbranded\nFDA has determined that you manufacture and offer for sale or distribution to customers in the United States e-liquid products that lack a marketing authorization order, including: Blueberry.\nThe tobacco products listed above are new tobacco products because they were not commercially marketed in the United States as of February 15, 2007. These products do not have FDA marketing authorization orders in effect under section 910(c)(1)(A)(i) of the FD&C Act and are not otherwise exempt from the marketing authorization requirement. Therefore, these products are adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, they are misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting these products was not provided as required by section 905(j) of the FD&C Act.\nConclusion and Requested Actions\nFDA has determined that your firm markets new tobacco products in the United States that lack premarket authorization. All new tobacco products on the market without the statutorily required premarket authorization are marketed unlawfully and are subject to enforcement action at FDA’s discretion.\nFor a list of products that received marketing granted orders, please visit our website: https:\u002F\u002Fwww.fda.gov\u002Ftobacco-products\u002Fmarket-and-distribute-tobacco-product\u002Ftobacco-products-marketing-orders#PMTAView%20all%20marketing%20granted.\nIt is your responsibility to ensure that all tobacco products you sell and\u002For distribute in the United States and all related labeling and\u002For advertising on any websites or other media (such as e-commerce, social networking, or search engine websites), and in any retail establishments in which you advertise, comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to address any violations of the FD&C Act, 21 U.S.C. § 301 et seq. or its implementing regulations relating to tobacco products including the tobacco regulations in 21 C.F.R. Parts 1140, 1141, or 1143, may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring these tobacco products into compliance with the FD&C Act.\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring these products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that these products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\nPlease note your reference number, ER2501118, in your response and direct your response to the following address:\nDEM-WL Response, Office of Compliance and Enforcement\nFDA Center for Tobacco Products\nc\u002Fo Document Control Center\nBuilding 71, Room G335\n10903 New Hampshire Avenue\nSilver Spring, MD 20993-0002\nIf you have any questions about the content of this letter, please contact CTPCompliance@fda.hhs.gov.\nSincerely,\n\u002FS\u002F\nJohn E. Verbeten\nDirector\nOffice of Compliance and Enforcement\nCenter for Tobacco Products","cool-vape-llc-700168-03132025","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcool-vape-llc-700168-03132025","2026-10-26T08:08:17.763733+00:00","2025-03-13","700168","2026-08-19T16:57:38.835+00:00","ER2501118",{"id":67,"raw":68,"subject":38,"body_html":72,"body_text":73,"firm_name":74,"letter_id":75,"created_at":76,"fei_number":19,"letter_url":77,"updated_at":78,"action_type":22,"case_status":23,"posted_date":79,"marcs_cms_no":80,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":81,"body_fetched_at":82,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":79,"medical_device_id":19,"response_letter_date":19},3183,[69,70,71,37,38,13,13,13],"\u003Ctime datetime=\"2021-08-26T19:00:00Z\">08\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-08-26T04:00:00Z\">08\u002F26\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcool-vapes-llc-617033-08262021\">Cool Vapes LLC\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Richard Marino\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cool Vapes LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7206 McKnight Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Pittsburgh\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>15237\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rj@coolvapes.com\"> rj@coolvapes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Marino:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Cool Vapes, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003Cbr>\n\u003Cbr>\n\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Cool Vapes Fuzzy Navel 30mL .3% e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 19,400 products listed with FDA. It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100202, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003Cbr>\n\u003Cbr>\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nRichard Marino\n\nRecipient Title\n\nOwner\n\nCool Vapes LLC\n\n7206 McKnight Road\n\nPittsburgh, PA 15237\n\nUnited States\n\nrj@coolvapes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Marino:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Cool Vapes, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Cool Vapes Fuzzy Navel 30mL .3% e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 19,400 products listed with FDA. It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100202, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Cool Vapes LLC","cool-vapes-llc-617033-08262021","2026-08-18T06:42:29.386127+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcool-vapes-llc-617033-08262021","2026-10-26T08:08:17.929133+00:00","2021-08-26","617033","Richard Marino","2026-08-20T02:39:39.812+00:00",{"id":84,"raw":85,"subject":92,"body_html":93,"body_text":94,"firm_name":95,"letter_id":96,"created_at":97,"fei_number":19,"letter_url":98,"updated_at":99,"action_type":22,"case_status":100,"posted_date":101,"marcs_cms_no":102,"product_type":103,"closeout_date":104,"issuing_office":89,"recipient_name":105,"body_fetched_at":106,"delivery_method":19,"recipient_title":19,"reference_number":19,"action_taken_date":107,"medical_device_id":19,"response_letter_date":19},3519,[86,87,88,89,90,13,91,13],"\u003Ctime datetime=\"2021-02-23T14:20:00Z\">02\u002F23\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-02-12T05:00:00Z\">02\u002F12\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcoopersurgical-inc-613339-02122021\">CooperSurgical, Inc.\u003C\u002Fa>","The Office of Prescription Drug Promotion (OPDP)","False &amp; Misleading Claims\u002FMisbranded","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcoopersurgical-inc-613339-01192022\">\u003Ctime datetime=\"2022-06-22T04:00:00Z\">06\u002F22\u002F2022\u003C\u002Ftime>\n\u003C\u002Fa>","False & Misleading Claims\u002FMisbranded","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Holly Sheffield\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>President\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>CooperSurgical, Inc.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>75 Corporate Drive\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Trumbull\u003C\u002Fspan>, \u003Cspan>CT\u003C\u002Fspan> \u003Cspan>06611\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>The Office of Prescription Drug Promotion (OPDP)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>RE: NDA 018680\u003C\u002Fstrong>\u003Cbr>\nPARAGARD (intrauterine copper contraceptive)\u003Cbr>\nMA 628\u003Cbr>\n\u003Cbr>\nDear Ms. Sheffield:\u003C\u002Fp>\n\n\u003Cp>The Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) has reviewed a direct-to-consumer video “sponsored by PARAGARD” (intrauterine copper contraceptive) (Paragard). This promotional communication, a video, entitled “Paragard: Family Planning During The Pandemic[,]” was presented on WBTS’s The Hub Today.\u003Csup>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> The video was submitted as a complaint to the FDA Bad Ad Program. The video is false or misleading in that it presents efficacy claims for Paragard, but fails to communicate any risk information associated with its use. Thus, the video misbrands Paragard within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) and makes its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(5). In addition, this promotional communication was not submitted at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i). These violations are concerning from a public health perspective because this promotional communication creates a misleading impression about the safety of Paragard.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Background\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Below are the indication and summary of the most serious and most common risks associated with the use of Paragard.\u003Csup>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem>\u003C\u002Fsup> According to the FDA-approved product labeling (PI):\u003C\u002Fp>\n\n\u003Cp>Paragard is indicated for prevention of pregnancy in females of reproductive potential for up to 10 years.\u003C\u002Fp>\n\n\u003Cp>Paragard is contraindicated in pregnancy or suspicion of pregnancy; in women with abnormalities of the uterus resulting in distortion of the uterine cavity, acute pelvic inflammatory disease, postpartum endometritis or postabortal endometritis in the past 3 months, known or suspected uterine or cervical malignancy, uterine bleeding of unknown etiology, untreated acute cervicitis or vaginitis or other lower genital tract infection, conditions associated with increased susceptibility to pelvic infections, Wilson’s disease, a previously placed IUD or IUS that has not been removed, or a hypersensitivity to any component of Paragard including to copper or any of the trace elements present in the copper component of Paragard. The PI also contains warnings and precautions regarding ectopic pregnancy, risks with intrauterine pregnancy, sepsis, pelvic inflammatory disease and endometritis, embedment, perforation, expulsion, Wilson’s disease, bleeding pattern alterations, magnetic resonance imaging (MRI) safety information, and medical diathermy. Adverse reactions reported with use of Paragard include anemia, backache, dysmenorrhea, dyspareunia, expulsion (complete or partial), prolonged menstrual flow, menstrual spotting, pain and cramping, and vaginitis.\u003C\u002Fp>\n\n\u003Cp>\u003Cem>Prior Communication\u003C\u002Fem>\u003C\u002Fp>\n\n\u003Cp>OPDP has expressed concerns regarding promotional materials for Paragard in a previous letter. On July 25, 2019, OPDP sent CooperSurgical, Inc. (CSI) an Untitled Letter for a Paragard Direct-to-Consumer television advertisement (2019 Untitled Letter) that omitted important risk information. CSI appears to be promoting Paragard without presenting the serious risks of the drug in a truthful and non-misleading manner, despite concerns previously expressed by OPDP.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>False or Misleading Risk Presentation\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Promotional materials misbrand a drug if they are false or misleading with respect to risk. The determination of whether promotional materials are misleading includes, among other things, not only representations made or suggested in promotional materials, but also failure to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the materials.\u003C\u002Fp>\n\n\u003Cp>The video begins with a voiceover statement, “This segment is sponsored by Paragard,” while simultaneously presenting the logo and proprietary and established names for Paragard along with the Paragard URL. The remainder of the video features a physician being interviewed and includes claims and representations about the use and\u002For benefits of Paragard. For example, superimposed text (SUPER) is included throughout the video,&nbsp;\u003Cstrong>“FAMILY PLANNING DURING THE PANDEMIC PARAGARD’S NON-HORMONAL OPTION”\u003C\u002Fstrong> (bolded emphasis original). However, the video fails to communicate any risk information about the product. We note that viewers are referred to “WWW.PARAGARD.COM” for further information about Paragard; however, this does not mitigate the complete omission of risk information from the video. By omitting the risks associated with Paragard, the video fails to provide material information about the consequences that may result from the use of the drug and creates a misleading impression about the drug’s safety. This misleading presentation is particularly concerning from a public health perspective due to the serious and potentially life-threatening risks associated with the drug, such as those contained in the WARNINGS AND PRECAUTIONS section of Paragard’s PI.\u003Cbr>\n\u003Cbr>\n\u003Cstrong>Failure to Submit Under Form FDA-2253\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the video was not submitted to OPDP under cover of Form FDA-2253 at the time of initial dissemination as required by 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Action\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>For the reasons discussed above, the video misbrands Paragard within the meaning of the FD&amp;C Act and makes its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(5). Furthermore, CSI did not comply with 21 CFR 314.81(b)(3)(i).\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you with an opportunity to address them. OPDP requests that CSI cease any violations of the FD&amp;C Act. Please submit a written response to this letter within 15 days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Paragard that contain representations like those described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Paragard.\u003C\u002Fp>\n\n\u003Cp>Failure to adequately address this matter may lead to regulatory action. If you believe that your products are not in violation of the FD&amp;C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 days from the date of receipt of this letter.\u003C\u002Fp>\n\n\u003Cp>Additionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. OPDP recommends that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Paragard; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\u003C\u002Fp>\n\n\u003Cp>The concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&amp;C Act and FDA implementing regulations.\u003Cbr>\n\u003Cbr>\nPlease direct your response to the undersigned at the \u003Cstrong>Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266\u003C\u002Fstrong>. A courtesy copy can be sent by facsimile to \u003Cspan>(301) 847-8444\u003Ca>\u003C\u002Fa>\u003C\u002Fspan>. To ensure timely delivery of your submissions, please use the full address above and include a prominent directional notation (e.g. a sticker) to indicate that the submission is intended for OPDP. Please refer to MA 628 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n{See appended electronic signature page}\u003Cbr>\nRobert Dean\u003Cbr>\nDirector\u003Cbr>\nDivision of Advertising &amp; Promotion Review 2\u003Cbr>\nOffice of Prescription Drug Promotion\u003Cbr>\n\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\u003Cbr>\n--------------------------------------------------------------------------------------------\u003Cbr>\n\u002Fs\u002F\u003Cbr>\n------------------------------------------------------------\u003C\u002Fp>\n\n\u003Cp>_____________________________\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>1\u003C\u002Fstrong>\u003C\u002Fem> This video is available on the internet at https:\u002F\u002Fwww.nbcboston.com\u002Fnews\u002Fnational-international\u002Fparagardfamily-planning-during-the-pandemic\u002F2207154\u002F (uploaded on October 5, 2020 and last accessed February 12, 2021).\u003C\u002Fp>\n\n\u003Cp>\u003Cem>\u003Cstrong>2\u003C\u002Fstrong>\u003C\u002Fem> This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional piece cited in this letter.\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Product:\n\nDrugs\n\nRecipient:\n\nRecipient Name\n\nHolly Sheffield\n\nRecipient Title\n\nPresident\n\nCooperSurgical, Inc.\n\n75 Corporate Drive\n\nTrumbull, CT 06611\n\nUnited States\n\nIssuing Office:\n\nThe Office of Prescription Drug Promotion (OPDP)\n\nUnited States\n\nWARNING LETTER\n\nRE: NDA 018680\n\nPARAGARD (intrauterine copper contraceptive)\n\nMA 628\n\nDear Ms. Sheffield:\n\nThe Office of Prescription Drug Promotion (OPDP) of the U.S. Food and Drug Administration (FDA) has reviewed a direct-to-consumer video “sponsored by PARAGARD” (intrauterine copper contraceptive) (Paragard). This promotional communication, a video, entitled “Paragard: Family Planning During The Pandemic[,]” was presented on WBTS’s The Hub Today.1 The video was submitted as a complaint to the FDA Bad Ad Program. The video is false or misleading in that it presents efficacy claims for Paragard, but fails to communicate any risk information associated with its use. Thus, the video misbrands Paragard within the meaning of the Federal Food, Drug, and Cosmetic Act (FD&C Act) and makes its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(5). In addition, this promotional communication was not submitted at the time of initial dissemination or publication as required by 21 CFR 314.81(b)(3)(i). These violations are concerning from a public health perspective because this promotional communication creates a misleading impression about the safety of Paragard.\n\nBackground\n\nBelow are the indication and summary of the most serious and most common risks associated with the use of Paragard.2 According to the FDA-approved product labeling (PI):\n\nParagard is indicated for prevention of pregnancy in females of reproductive potential for up to 10 years.\n\nParagard is contraindicated in pregnancy or suspicion of pregnancy; in women with abnormalities of the uterus resulting in distortion of the uterine cavity, acute pelvic inflammatory disease, postpartum endometritis or postabortal endometritis in the past 3 months, known or suspected uterine or cervical malignancy, uterine bleeding of unknown etiology, untreated acute cervicitis or vaginitis or other lower genital tract infection, conditions associated with increased susceptibility to pelvic infections, Wilson’s disease, a previously placed IUD or IUS that has not been removed, or a hypersensitivity to any component of Paragard including to copper or any of the trace elements present in the copper component of Paragard. The PI also contains warnings and precautions regarding ectopic pregnancy, risks with intrauterine pregnancy, sepsis, pelvic inflammatory disease and endometritis, embedment, perforation, expulsion, Wilson’s disease, bleeding pattern alterations, magnetic resonance imaging (MRI) safety information, and medical diathermy. Adverse reactions reported with use of Paragard include anemia, backache, dysmenorrhea, dyspareunia, expulsion (complete or partial), prolonged menstrual flow, menstrual spotting, pain and cramping, and vaginitis.\n\nPrior Communication\n\nOPDP has expressed concerns regarding promotional materials for Paragard in a previous letter. On July 25, 2019, OPDP sent CooperSurgical, Inc. (CSI) an Untitled Letter for a Paragard Direct-to-Consumer television advertisement (2019 Untitled Letter) that omitted important risk information. CSI appears to be promoting Paragard without presenting the serious risks of the drug in a truthful and non-misleading manner, despite concerns previously expressed by OPDP.\n\nFalse or Misleading Risk Presentation\n\nPromotional materials misbrand a drug if they are false or misleading with respect to risk. The determination of whether promotional materials are misleading includes, among other things, not only representations made or suggested in promotional materials, but also failure to reveal facts material in light of the representations made or with respect to consequences that may result from the use of the drug as recommended or suggested in the materials.\n\nThe video begins with a voiceover statement, “This segment is sponsored by Paragard,” while simultaneously presenting the logo and proprietary and established names for Paragard along with the Paragard URL. The remainder of the video features a physician being interviewed and includes claims and representations about the use and\u002For benefits of Paragard. For example, superimposed text (SUPER) is included throughout the video, “FAMILY PLANNING DURING THE PANDEMIC PARAGARD’S NON-HORMONAL OPTION” (bolded emphasis original). However, the video fails to communicate any risk information about the product. We note that viewers are referred to “WWW.PARAGARD.COM” for further information about Paragard; however, this does not mitigate the complete omission of risk information from the video. By omitting the risks associated with Paragard, the video fails to provide material information about the consequences that may result from the use of the drug and creates a misleading impression about the drug’s safety. This misleading presentation is particularly concerning from a public health perspective due to the serious and potentially life-threatening risks associated with the drug, such as those contained in the WARNINGS AND PRECAUTIONS section of Paragard’s PI.\n\nFailure to Submit Under Form FDA-2253\n\nFDA regulations require any labeling or advertising devised for promotion of the drug product to be submitted at the time of initial dissemination of the labeling and at the time of initial publication of the advertisement for a prescription drug product. Each submission is required to be accompanied by a completed transmittal Form FDA-2253 (Transmittal of Advertisements and Promotional Labeling for Drugs for Human Use) and is required to include a copy of the product’s current professional labeling. A copy of the video was not submitted to OPDP under cover of Form FDA-2253 at the time of initial dissemination as required by 21 CFR 314.81(b)(3)(i).\n\nConclusion and Requested Action\n\nFor the reasons discussed above, the video misbrands Paragard within the meaning of the FD&C Act and makes its distribution violative. 21 U.S.C. 352(a), (n); 321(n); 331(a). See 21 CFR 202.1(e)(5). Furthermore, CSI did not comply with 21 CFR 314.81(b)(3)(i).\n\nThis letter notifies you of our concerns and provides you with an opportunity to address them. OPDP requests that CSI cease any violations of the FD&C Act. Please submit a written response to this letter within 15 days from the date of receipt, addressing the concerns described in this letter, listing all other promotional communications (with the 2253 submission date) for Paragard that contain representations like those described above, and explaining any plan for discontinuing use of such communications, or for ceasing distribution of Paragard.\n\nFailure to adequately address this matter may lead to regulatory action. If you believe that your products are not in violation of the FD&C Act, please include in your submission to us your reasoning and any supporting information for our consideration within 15 days from the date of receipt of this letter.\n\nAdditionally, we request that your submission include a comprehensive plan of action to disseminate truthful, non-misleading, and complete corrective communication(s) about the concern(s) discussed in this letter. The corrective communication(s) should be disseminated to the audience(s) that received the promotional communication(s) identified in the opening paragraph of this letter. OPDP recommends that corrective communication(s) include a description of the promotional communication(s) identified in this letter, which misbrand Paragard; include a summary of the concern(s) described in this letter; and provide information to correct each of these concern(s). Corrective communication(s) should be free of promotional claims and presentations. To the extent possible, corrective communication(s) should be distributed using the same media, and generally for the same duration of time and with the same frequency as the promotional communication(s) identified in the opening paragraph of this letter.\n\nThe concerns discussed in this letter do not necessarily constitute an exhaustive list of potential violations. It is your responsibility to ensure compliance with each applicable requirement of the FD&C Act and FDA implementing regulations.\n\nPlease direct your response to the undersigned at the Food and Drug Administration, Center for Drug Evaluation and Research, Office of Prescription Drug Promotion, 5901-B Ammendale Road, Beltsville, Maryland 20705-1266. A courtesy copy can be sent by facsimile to (301) 847-8444. To ensure timely delivery of your submissions, please use the full address above and include a prominent directional notation (e.g. a sticker) to indicate that the submission is intended for OPDP. Please refer to MA 628 in addition to the NDA number in all future correspondence relating to this particular matter. All correspondence should include a subject line that clearly identifies the submission as a Response to Warning Letter.\n\nSincerely,\n\n{See appended electronic signature page}\n\nRobert Dean\n\nDirector\n\nDivision of Advertising & Promotion Review 2\n\nOffice of Prescription Drug Promotion\n\n--------------------------------------------------------------------------------------------\n\nThis is a representation of an electronic record that was signed electronically. Following this are manifestations of any and all electronic signatures for this electronic record.\n\n--------------------------------------------------------------------------------------------\n\n\u002Fs\u002F\n\n------------------------------------------------------------\n\n_____________________________\n\n1 This video is available on the internet at https:\u002F\u002Fwww.nbcboston.com\u002Fnews\u002Fnational-international\u002Fparagardfamily-planning-during-the-pandemic\u002F2207154\u002F (uploaded on October 5, 2020 and last accessed February 12, 2021).\n\n2 This information is for background purposes only and does not necessarily represent the risk information that should be included in the promotional piece cited in this letter.","CooperSurgical, Inc.","coopersurgical-inc-613339-02122021","2026-08-18T06:42:29.460824+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcoopersurgical-inc-613339-02122021","2026-10-26T08:08:18.137841+00:00","Closed Out","2021-02-23","613339","Drugs","2022-06-22","Holly Sheffield","2026-08-20T03:21:42.84+00:00","2021-02-12",{"id":109,"raw":110,"subject":116,"body_html":117,"body_text":118,"firm_name":119,"letter_id":120,"created_at":121,"fei_number":19,"letter_url":122,"updated_at":123,"action_type":22,"case_status":23,"posted_date":124,"marcs_cms_no":125,"product_type":126,"closeout_date":19,"issuing_office":114,"recipient_name":127,"body_fetched_at":128,"delivery_method":129,"recipient_title":19,"reference_number":130,"action_taken_date":131,"medical_device_id":19,"response_letter_date":19},2977,[111,112,113,114,115,13,13,13],"\u003Ctime datetime=\"2021-12-14T14:20:00Z\">12\u002F14\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-12-15T05:00:00Z\">12\u002F15\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcooper-institute-619233-12152021\">Cooper Institute\u003C\u002Fa>","Office of Biological Products Operations – Division 2","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues &amp; Cellular Products (HCT\u002FPs)","Deviations\u002FCFR\u002FRegulations for Human Cells, Tissues & Cellular Products (HCT\u002FPs)","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n              \u003Cdt>Reference #:\u003C\u002Fdt> \n        \u003Cdd>OPBO 21-619233\u003C\u002Fdd>\n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Biologics                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Dr. Ching-Fong James Chuong, M.D.\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Medical Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cooper Institute\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>7500 Beechnut Street, Suite #308\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Houston\u003C\u002Fspan>, \u003Cspan>TX\u003C\u002Fspan> \u003Cspan>77074\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Biological Products Operations – Division 2\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>Warning Letter #OPBO 21-619233&nbsp;\u003Cbr>\nDr. Ching-Fong James Chuong, M.D.\u003Cbr>\nMedical Director\u003Cbr>\nCooper Institute for Advanced Reproductive Medicine\u003Cbr>\n7500 Beechnut Street, Suite #308\u003Cbr>\nHouston, TX 77074\u003C\u002Fp>\n\n\u003Cp>Dear Dr. Chuong:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your firm, Cooper Institute for Advanced Reproductive Medicine, located at 7500 Beechnut Street, Suite #308, Houston, TX, from July 8, 2021 through July 19, 2021. During the inspection, an FDA Investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 (21 CFR 1271), and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\u003C\u002Fp>\n\n\u003Cp>The deviations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. The items of concern include, but are not limited to, the following:\u003C\u002Fp>\n\n\u003Cp>1.&nbsp;&nbsp; &nbsp;Failure to test a specimen from an anonymous or directed reproductive donor of cells or tissue, whether viable or non-viable, for evidence of infection due to relevant communicable disease agents [21 CFR 1271.85(a)]. For example:\u003Cbr>\n&nbsp;\u003Cbr>\na.&nbsp;&nbsp; &nbsp;Living HCT\u002FP donors should be tested for West Nile Virus (WNV) using an FDA-licensed Nucleic Acid Test (NAT) donor screening test for HCT\u002FPs recovered between June 1st and October 31st every year. Two anonymous oocyte donors (\u003Cstrong>(b)(6)\u003C\u002Fstrong>) were not tested for WNV during that time period.\u003C\u002Fp>\n\n\u003Cp>b.&nbsp;&nbsp; &nbsp;The donor specimen collected from anonymous oocyte donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> on July 8, 2020, was not tested for human immunodeficiency virus, types 1 and 2 (HIV-1\u002F2), hepatitis B virus (HBV), hepatitis C virus (HCV), and Treponema pallidum at the time of recovery on July 14, 2020.&nbsp;\u003C\u002Fp>\n\n\u003Cp>2.&nbsp;&nbsp; &nbsp;Failure to test a specimen from an anonymous or directed reproductive donor of cells or tissue, to adequately and appropriately reduce the risk of transmission of relevant communicable disease agents of the genitourinary tract. The reproductive cells or tissue were not recovered by a method that ensured freedom from contamination of the cells or tissue by infectious disease organisms that may be present in the genitourinary tract [21 CFR 1271.85(c)]. For example, there is no record that anonymous oocyte donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> was tested for \u003Cem>Chlamydia trachomatis\u003C\u002Fem> and \u003Cem>Neisseria gonorrhea\u003C\u002Fem> at the time of oocyte recovery.\u003C\u002Fp>\n\n\u003Cp>3.&nbsp;&nbsp; &nbsp;Failure of a responsible person to determine and document the eligibility of a donor of reproductive cells or tissue based on the results of donor screening and testing [21 CFR 1271.50(a)]. For example, the records for the following anonymous oocyte donors did not contain documentation of the donor eligibility determination, including the name of the responsible person who made the determination, the date of the determination, and documentation that the donor was determined “eligible:”&nbsp;\u003C\u002Fp>\n\n\u003Cp>a.&nbsp;&nbsp; &nbsp;Oocytes were recovered from anonymous donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> on June 28, 2021.\u003Cbr>\nb.&nbsp;&nbsp; &nbsp;Oocytes were recovered from anonymous donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> on April 19, 2021.\u003Cbr>\nc.&nbsp;&nbsp; &nbsp;Oocytes were recovered from anonymous donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> on February 6, 2021.\u003Cbr>\nd.&nbsp;&nbsp; &nbsp;Oocytes were recovered from anonymous donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> on November 28, 2020.\u003Cbr>\ne.&nbsp;&nbsp; &nbsp;Oocytes were recovered from anonymous donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> on July 14, 2020.\u003Cbr>\nf.&nbsp;&nbsp; &nbsp;Oocytes were recovered from anonymous donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> on March 18, 2020.\u003C\u002Fp>\n\n\u003Cp>4.&nbsp;&nbsp; &nbsp;Failure to screen a donor of reproductive cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)]. Under 21 CFR 1271.75(a), you must screen a donor of cells or tissue by reviewing the donor’s “relevant medical records” for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases. 21 CFR 1271.3(s) defines the term “relevant medical records” to include a current donor medical history interview and a current report of the physical examination of a living donor. For example:\u003Cbr>\n&nbsp;\u003Cbr>\na.&nbsp;&nbsp; &nbsp;Your Donor\u002FSurrogate Eligibility Questionnaire is a relevant medical record used to determine donor eligibility. However, your questionnaire does not include screening for all conditions and\u002For behaviors that increase a donor’s relevant communicable disease risk. For example, questions for the following risk factors for relevant communicable disease agents and diseases are missing from your screening forms:&nbsp;\u003C\u002Fp>\n\n\u003Cp>i.&nbsp;&nbsp; &nbsp;Persons who have had a medical diagnosis of Zika Virus (ZIKV) in the past 6 months\u003C\u002Fp>\n\n\u003Cp>ii.&nbsp;&nbsp; &nbsp;Persons who resided in, or travelled to, an area with an increased risk for ZIKV transmission within the past 6 months.\u003C\u002Fp>\n\n\u003Cp>iii.&nbsp;&nbsp; &nbsp;Persons who have had sex within the past 6 months with a person who has either of the risk factors listed in items i or ii, above.\u003C\u002Fp>\n\n\u003Cp>iv.&nbsp;&nbsp; &nbsp;Persons who have been diagnosed with dementia or any degenerative or demyelinating disease of the central nervous system or other neurological disease of unknown etiology.\u003C\u002Fp>\n\n\u003Cp>v.&nbsp;&nbsp; &nbsp;Persons who are at increased risk for CJD if they have received a non-synthetic dura mater transplant.\u003C\u002Fp>\n\n\u003Cp>vi.&nbsp;&nbsp; &nbsp;Persons who received any transfusion of blood or blood components in the \u003Cstrong>France\u003C\u002Fstrong> between 1980 and the present.\u003C\u002Fp>\n\n\u003Cp>vii.&nbsp;&nbsp; &nbsp;Persons who spent 5 years or more cumulatively in Europe from 1980 until the present (note this criterion includes time spent in the U.K. from \u003Cstrong>1980 through 1996\u003C\u002Fstrong>). Your questionnaire only asks, “Have you lived cumulatively in Europe for 5 years or more from 1980 through 1996?”\u003C\u002Fp>\n\n\u003Cp>b.&nbsp;&nbsp; &nbsp;The records for anonymous oocyte donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> lack documentation of a current report of the physical examination of the donor. Oocytes were recovered from donor \u003Cstrong>(b)(6)\u003C\u002Fstrong> on June 28, 2021.\u003C\u002Fp>\n\n\u003Cp>5.&nbsp;&nbsp; &nbsp;Failure to establish and maintain procedures for all steps performed in testing, screening, and determining eligibility, and complying with all other requirements of Subpart C “Donor Eligibility” in 21 CFR Part 1271.45-1271.90. “Establish and maintain” means define, document (in writing or electronically), and implement; then follow, review, and as needed, revise on an ongoing basis [21 CFR 1271.47(a)]. Your firm does not have procedures for all steps that you perform in donor testing, screening, and determining donor eligibility of semen and oocyte donors.&nbsp;\u003C\u002Fp>\n\n\u003Cp>To date, we have not received a response to the observations on the FDA-483 provided to you at the close of the inspection; therefore, we are unable to evaluate what, if any, corrective actions you have implemented, or plan to implement and whether they are adequate to address our concerns. We acknowledge the corrections your firm made during the inspection to the “Donor\u002FSurrogate Eligibility Questionnaire” to include the screening for ZIKV. In addition, you stated at the close of the inspection on July 19, 2021 that you have committed to ensuring donors are tested for West Nile Virus using an FDA-licensed NAT donor screening test for HCT\u002FPs recovered between June 1st and October 31st every year. Please note these are requirements per 21 CFR 1271.75(a)(1) and 21 CFR 1271.85(a), and therefore all donors should be evaluated using your revised questionnaire and tested accordingly. These will be verified during the next inspection of your facility.\u003C\u002Fp>\n\n\u003Cp>The deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment is in compliance with all applicable requirements of the federal regulations. &nbsp;You are responsible for reviewing your firm’s operations as a whole to assure that you are in compliance with the law.\u003C\u002Fp>\n\n\u003Cp>Please note that if you still have oocytes and\u002For semen in storage from donors whose screening and\u002For testing was not completed in accordance with 21 CFR Part 1271, FDA considers the donor eligibility determinations to be incomplete for these donors. For example, donors who were screened using a donor history questionnaire that was missing required screening questions, and donors who are missing a required donor history questionnaire, physical examination, and\u002For testing for relevant communicable disease agents and diseases. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine.&nbsp;\u003C\u002Fp>\n\n\u003Cp>Should the need arise in the future to remove any of these oocytes or semen from quarantine, either for use in your own establishment or for transport to another establishment, you may request an exemption or alternative from a requirement in subpart C 21 CFR Part 1271, as specified in 21 CFR 1271.155 (additional information can be found at: &nbsp;https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Ftissue-tissue-products\u002Fexemptions-and-alternatives). &nbsp;Please note that 21 CFR 1271.155 requires that you provide justification for use of HCT\u002FPs from these donors, as well as information on how you have mitigated the risk consistent with the goals of protecting the public health and\u002For preventing the introduction, transmission, or spread of communicable diseases. Before any of these HCT\u002FPs can be removed from quarantine, the request must be granted by FDA.\u003C\u002Fp>\n\n\u003Cp>If you still have embryos in storage for which the donor eligibility requirements under Part 1271, Subpart C are not met, please note that FDA considers the donor eligibility determinations to be incomplete for these donors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine. &nbsp;Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may release these HCT\u002FPs from quarantine (21 CFR 1271.90(b)) provided they are labeled in accordance with the applicable regulations at 21 CFR 1271.90(c).\u003C\u002Fp>\n\n\u003Cp>You should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice. &nbsp;\u003C\u002Fp>\n\n\u003Cp>We request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. &nbsp;Include any documentation necessary to show that correction has been achieved. &nbsp;If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\u003C\u002Fp>\n\n\u003Cp>Your response should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food &amp; Drug Administration, Office of Biological Product Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. &nbsp;If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 271-1242 x 104 or via e-mail.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002Fs\u002F\u003Cbr>\nKarlton Watson\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Biological Products Operations – Division 2\u003Cbr>\n&nbsp;\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE SIGNATURE REQUIRED\n\nReference #:\n\nOPBO 21-619233\n\nProduct:\n\nBiologics\n\nRecipient:\n\nRecipient Name\n\nDr. Ching-Fong James Chuong, M.D.\n\nRecipient Title\n\nMedical Director\n\nCooper Institute\n\n7500 Beechnut Street, Suite #308\n\nHouston, TX 77074\n\nUnited States\n\nIssuing Office:\n\nOffice of Biological Products Operations – Division 2\n\nUnited States\n\nWarning Letter #OPBO 21-619233\n\nDr. Ching-Fong James Chuong, M.D.\n\nMedical Director\n\nCooper Institute for Advanced Reproductive Medicine\n\n7500 Beechnut Street, Suite #308\n\nHouston, TX 77074\n\nDear Dr. Chuong:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your firm, Cooper Institute for Advanced Reproductive Medicine, located at 7500 Beechnut Street, Suite #308, Houston, TX, from July 8, 2021 through July 19, 2021. During the inspection, an FDA Investigator documented significant deviations from the regulations for human cells, tissues, and cellular and tissue-based products (HCT\u002FPs) set forth in Title 21, Code of Federal Regulations (CFR) Part 1271 (21 CFR 1271), and issued under the authority of Section 361 of the Public Health Service Act [42 U.S.C. § 264].\n\nThe deviations documented on the Form FDA-483, List of Inspectional Observations, were presented to and discussed with you at the conclusion of the inspection. The items of concern include, but are not limited to, the following:\n\n1. Failure to test a specimen from an anonymous or directed reproductive donor of cells or tissue, whether viable or non-viable, for evidence of infection due to relevant communicable disease agents [21 CFR 1271.85(a)]. For example:\n\na. Living HCT\u002FP donors should be tested for West Nile Virus (WNV) using an FDA-licensed Nucleic Acid Test (NAT) donor screening test for HCT\u002FPs recovered between June 1st and October 31st every year. Two anonymous oocyte donors ((b)(6)) were not tested for WNV during that time period.\n\nb. The donor specimen collected from anonymous oocyte donor (b)(6) on July 8, 2020, was not tested for human immunodeficiency virus, types 1 and 2 (HIV-1\u002F2), hepatitis B virus (HBV), hepatitis C virus (HCV), and Treponema pallidum at the time of recovery on July 14, 2020.\n\n2. Failure to test a specimen from an anonymous or directed reproductive donor of cells or tissue, to adequately and appropriately reduce the risk of transmission of relevant communicable disease agents of the genitourinary tract. The reproductive cells or tissue were not recovered by a method that ensured freedom from contamination of the cells or tissue by infectious disease organisms that may be present in the genitourinary tract [21 CFR 1271.85(c)]. For example, there is no record that anonymous oocyte donor (b)(6) was tested for Chlamydia trachomatis and Neisseria gonorrhea at the time of oocyte recovery.\n\n3. Failure of a responsible person to determine and document the eligibility of a donor of reproductive cells or tissue based on the results of donor screening and testing [21 CFR 1271.50(a)]. For example, the records for the following anonymous oocyte donors did not contain documentation of the donor eligibility determination, including the name of the responsible person who made the determination, the date of the determination, and documentation that the donor was determined “eligible:”\n\na. Oocytes were recovered from anonymous donor (b)(6) on June 28, 2021.\n\nb. Oocytes were recovered from anonymous donor (b)(6) on April 19, 2021.\n\nc. Oocytes were recovered from anonymous donor (b)(6) on February 6, 2021.\n\nd. Oocytes were recovered from anonymous donor (b)(6) on November 28, 2020.\n\ne. Oocytes were recovered from anonymous donor (b)(6) on July 14, 2020.\n\nf. Oocytes were recovered from anonymous donor (b)(6) on March 18, 2020.\n\n4. Failure to screen a donor of reproductive cells or tissue by reviewing the donor’s relevant medical records for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases [21 CFR 1271.75(a)]. Under 21 CFR 1271.75(a), you must screen a donor of cells or tissue by reviewing the donor’s “relevant medical records” for risk factors for, and clinical evidence of, relevant communicable disease agents and diseases. 21 CFR 1271.3(s) defines the term “relevant medical records” to include a current donor medical history interview and a current report of the physical examination of a living donor. For example:\n\na. Your Donor\u002FSurrogate Eligibility Questionnaire is a relevant medical record used to determine donor eligibility. However, your questionnaire does not include screening for all conditions and\u002For behaviors that increase a donor’s relevant communicable disease risk. For example, questions for the following risk factors for relevant communicable disease agents and diseases are missing from your screening forms:\n\ni. Persons who have had a medical diagnosis of Zika Virus (ZIKV) in the past 6 months\n\nii. Persons who resided in, or travelled to, an area with an increased risk for ZIKV transmission within the past 6 months.\n\niii. Persons who have had sex within the past 6 months with a person who has either of the risk factors listed in items i or ii, above.\n\niv. Persons who have been diagnosed with dementia or any degenerative or demyelinating disease of the central nervous system or other neurological disease of unknown etiology.\n\nv. Persons who are at increased risk for CJD if they have received a non-synthetic dura mater transplant.\n\nvi. Persons who received any transfusion of blood or blood components in the France between 1980 and the present.\n\nvii. Persons who spent 5 years or more cumulatively in Europe from 1980 until the present (note this criterion includes time spent in the U.K. from 1980 through 1996). Your questionnaire only asks, “Have you lived cumulatively in Europe for 5 years or more from 1980 through 1996?”\n\nb. The records for anonymous oocyte donor (b)(6) lack documentation of a current report of the physical examination of the donor. Oocytes were recovered from donor (b)(6) on June 28, 2021.\n\n5. Failure to establish and maintain procedures for all steps performed in testing, screening, and determining eligibility, and complying with all other requirements of Subpart C “Donor Eligibility” in 21 CFR Part 1271.45-1271.90. “Establish and maintain” means define, document (in writing or electronically), and implement; then follow, review, and as needed, revise on an ongoing basis [21 CFR 1271.47(a)]. Your firm does not have procedures for all steps that you perform in donor testing, screening, and determining donor eligibility of semen and oocyte donors.\n\nTo date, we have not received a response to the observations on the FDA-483 provided to you at the close of the inspection; therefore, we are unable to evaluate what, if any, corrective actions you have implemented, or plan to implement and whether they are adequate to address our concerns. We acknowledge the corrections your firm made during the inspection to the “Donor\u002FSurrogate Eligibility Questionnaire” to include the screening for ZIKV. In addition, you stated at the close of the inspection on July 19, 2021 that you have committed to ensuring donors are tested for West Nile Virus using an FDA-licensed NAT donor screening test for HCT\u002FPs recovered between June 1st and October 31st every year. Please note these are requirements per 21 CFR 1271.75(a)(1) and 21 CFR 1271.85(a), and therefore all donors should be evaluated using your revised questionnaire and tested accordingly. These will be verified during the next inspection of your facility.\n\nThe deviations identified above are not intended to be an all-inclusive list of deficiencies at your facility. It is your responsibility to ensure that your establishment is in compliance with all applicable requirements of the federal regulations. You are responsible for reviewing your firm’s operations as a whole to assure that you are in compliance with the law.\n\nPlease note that if you still have oocytes and\u002For semen in storage from donors whose screening and\u002For testing was not completed in accordance with 21 CFR Part 1271, FDA considers the donor eligibility determinations to be incomplete for these donors. For example, donors who were screened using a donor history questionnaire that was missing required screening questions, and donors who are missing a required donor history questionnaire, physical examination, and\u002For testing for relevant communicable disease agents and diseases. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine.\n\nShould the need arise in the future to remove any of these oocytes or semen from quarantine, either for use in your own establishment or for transport to another establishment, you may request an exemption or alternative from a requirement in subpart C 21 CFR Part 1271, as specified in 21 CFR 1271.155 (additional information can be found at: https:\u002F\u002Fwww.fda.gov\u002Fvaccines-blood-biologics\u002Ftissue-tissue-products\u002Fexemptions-and-alternatives). Please note that 21 CFR 1271.155 requires that you provide justification for use of HCT\u002FPs from these donors, as well as information on how you have mitigated the risk consistent with the goals of protecting the public health and\u002For preventing the introduction, transmission, or spread of communicable diseases. Before any of these HCT\u002FPs can be removed from quarantine, the request must be granted by FDA.\n\nIf you still have embryos in storage for which the donor eligibility requirements under Part 1271, Subpart C are not met, please note that FDA considers the donor eligibility determinations to be incomplete for these donors. Therefore, as required by 21 CFR 1271.60(a), you must keep these HCT\u002FPs in quarantine. Should the need arise in the future to remove any of these HCT\u002FPs from quarantine, either for use in your own establishment or for transport to another establishment, you may release these HCT\u002FPs from quarantine (21 CFR 1271.90(b)) provided they are labeled in accordance with the applicable regulations at 21 CFR 1271.90(c).\n\nYou should take prompt action to correct the violations addressed in this letter and prevent their recurrence. Failure to promptly correct these violations may result in regulatory action being initiated by the FDA without further notice.\n\nWe request that you respond in writing within fifteen (15) working days from your receipt of this letter, outlining the specific steps you have taken or plan to take to correct the noted violations, including an explanation of how you plan to prevent these violations, or similar violations, from occurring again. Include any documentation necessary to show that correction has been achieved. If you cannot complete all corrective actions within fifteen (15) working days, please explain the reason for your delay and the timeframe within which the remaining corrections will be completed.\n\nYour response should be sent to the following address: Young Mi Yoon, Compliance Officer, U.S. Food & Drug Administration, Office of Biological Product Operations – Division 2, 222 W. 7th Avenue, #25, Room 122, Anchorage, AK 99513 or emailed to YoungMi.Yoon@fda.hhs.gov. If you should have any questions, please contact Young Mi Yoon, Compliance Officer at (907) 271-1242 x 104 or via e-mail.\n\nSincerely,\n\n\u002Fs\u002F\n\nKarlton Watson\n\nProgram Division Director\n\nOffice of Biological Products Operations – Division 2","Cooper Institute","cooper-institute-619233-12152021","2026-08-18T06:42:29.262718+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcooper-institute-619233-12152021","2026-10-26T08:08:18.034183+00:00","2021-12-14","619233","Biologics","Dr. Ching-Fong James Chuong, M.D.","2026-08-20T02:20:30.35+00:00","VIA UNITED PARCEL SERVICE SIGNATURE REQUIRED","OPBO 21-619233","2021-12-15",{"id":133,"raw":134,"subject":139,"body_html":140,"body_text":141,"firm_name":142,"letter_id":143,"created_at":144,"fei_number":19,"letter_url":145,"updated_at":146,"action_type":22,"case_status":23,"posted_date":147,"marcs_cms_no":148,"product_type":26,"closeout_date":19,"issuing_office":149,"recipient_name":150,"body_fetched_at":151,"delivery_method":152,"recipient_title":19,"reference_number":19,"action_taken_date":153,"medical_device_id":19,"response_letter_date":19},1674,[135,136,137,138,139,13,13,13],"\u003Ctime datetime=\"2023-12-26T14:20:00Z\">12\u002F26\u002F2023\u003C\u002Ftime>\n","\u003Ctime datetime=\"2023-11-24T05:00:00Z\">11\u002F24\u002F2023\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcooperstown-cheese-company-llc-667551-11242023\">Cooperstown Cheese Company, LLC\u003C\u002Fa>"," Division of Human and Animal Food Operations East I","CGMP\u002FFood\u002FPrepared, Packed or Held Under Insanitary Conditions\u002FAdulterated\u002FL. monocytogenes","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Robert C. Sweitzer and Ms. Sharon Tomaselli\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Co-Owners\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cooperstown Cheese Company, LLC\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>107 Oxbow Road\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Milford\u003C\u002Fspan>, \u003Cspan>NY\u003C\u002Fspan> \u003Cspan>13807-1131\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd> Division of Human and Animal Food Operations East I\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n  \u003Cdiv>\n    \u003Cdiv>Secondary Issuing Offices\u003C\u002Fdiv>\n          \u003Cdiv>\n              \u003Cdiv>    \u003Cbr>\n    \n     \n        \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n    \n    \n    \n    \n\u003C\u002Fdiv>\n              \u003C\u002Fdiv>\n      \u003C\u002Fdiv>\n\n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nCMS # 667551\u003C\u002Fp>\n\n\u003Cp>11\u002F24\u002F2023\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Sweitzer and Ms. Tomaselli:\u003C\u002Fp>\n\n\u003Cp>The United States Food and Drug Administration (FDA) conducted an inspection of your ready-to-eat (RTE) raw milk cheese manufacturing facility located at 107 Oxbow Road., Milford, NY 13807-1131 from June 21 through July 28, 2023. During our inspection of your facility, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analysis of the environmental swabs found the presence of \u003Cem>Listeria monocytogenes\u003C\u002Fem> (\u003Cem>L. monocytogenes\u003C\u002Fem>), a human pathogen, in your facility. At the conclusion of the inspection, the FDA investigators issued your facility a Form FDA 483 (FDA-483), Inspectional Observations.\u003C\u002Fp>\n\n\u003Cp>Based on FDA’s inspectional findings and the analytical results for samples collected from your production environment, we have determined that the RTE cheese products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You may find the Act and further information about the CGMP &amp; PC rule through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\u003C\u002Fp>\n\n\u003Cp>We received your responses to FDA’s environmental sample findings via email on July 13, 17, 18, and 19, and August 3, 2023, and to the FDA-483 via email on August 11, 2023, describing corrective actions taken and planned by your firm. Based on our review of the inspectional findings and the responses that your firm provided, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\u003Cbr>\n\u003Cbr>\n\u003Cu>\u003Cstrong>Pathogen Findings\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>\u003Cem>L. monocytogenes\u003C\u002Fem> is a pathogenic bacterium that is widespread in the environment and may be introduced into a food processing facility from raw materials, humans, or equipment. Without proper controls, it can proliferate in food processing facilities where it may contaminate food. Therefore, it is essential to identify the areas of the food processing plant where this organism is able to grow and survive and to apply controls or take corrective actions as necessary to eradicate the organism. Consuming foods contaminated with \u003Cem>L. monocytogenes\u003C\u002Fem> can lead to a severe, sometimes life-threatening illness called listeriosis, which is a major public health concern due to the severity of the disease, its high case-fatality rate, its long incubation time, and its tendency to affect individuals with underlying conditions.\u003C\u002Fp>\n\n\u003Cp>FDA laboratory analysis of environmental sample #1221906 collected at your facility on June 21, 2023 confirmed that four (4) of fifty (50) environmental swabs were positive for \u003Cem>L. monocytogenes\u003C\u002Fem>, and FDA laboratory analysis of environmental sample #1228986 collected at your facility on June 26, 2023 confirmed that four (4) of fifty six (56) environmental swabs were positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. Of the positive findings, one (1) of the \u003Cem>L. monocytogenes\u003C\u002Fem> positive swabs was collected from the food contact surface of a cutting board that was being used to cut RTE Jersey Girl cheese.\u003C\u002Fp>\n\n\u003Cp>Furthermore, dating back to 2017, your firm has had history of finished product samples that have tested positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. In 2017, New York State Department of Agriculture and Markets (NYSDAM) collected a finished product sample of your firm’s Toma Celena cheese (lot #51017) which tested positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. In response to this finding, your firm tested \u003Cstrong>(b)(4)\u003C\u002Fstrong> lots of finished products and found two additional lots (lots #52417 and #60717) to be positive for \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>Whole genome sequencing (WGS) was conducted on the above referenced \u003Cem>L. monocytogenes\u003C\u002Fem> isolates. Based on the results of the WGS analysis, the environmental swabs collected at your facility during FDA’s most recent inspection and finished product samples from 2017 represent four (4) different strains of \u003Cem>L. monocytogenes\u003C\u002Fem>. None of them matched any clinical isolates. We advised you of the importance of these WGS results via a conference call on July 14, 2023, and again on July 20, 2023.\u003C\u002Fp>\n\n\u003Cp>The presence of \u003Cem>L. monocytogenes\u003C\u002Fem> in your facility and your products is significant in that it demonstrates your sanitation efforts are inadequate to effectively control pathogens in your facility to prevent contamination of food. Appropriate control of \u003Cem>L. monocytogenes\u003C\u002Fem> in a food processing environment requires knowledge of the unique characteristics of the organism and implementing the corresponding hygienic practices necessary to control this pathogen. Our findings indicate that your firm is neither achieving satisfactory control against the presence of \u003Cem>L. monocytogenes\u003C\u002Fem> within your facility nor implementing effective methods and controls to eliminate this human pathogen or minimize exposure to food and food-contact surfaces. Once it is established in a production area, personnel or equipment can facilitate the pathogen’s movement and contamination of food-contact surfaces and finished product. It is essential to identify the harborage sites in the food processing plant and equipment where this organism is able to grow and survive and to take such corrective actions as are necessary to eradicate the organism.\u003C\u002Fp>\n\n\u003Cp>Additionally, FDA has repeatedly detected \u003Cem>Listeria innocua\u003C\u002Fem> (\u003Cem>L. innocua\u003C\u002Fem>), a non-pathogenic \u003Cem>Listeria\u003C\u002Fem> species, in environmental samples collected from your firm during the current and previous FDA inspections. FDA laboratory analysis of environmental samples collected on June 21, 2023 confirmed that three (3) of fifty (50) environmental swabs were positive for \u003Cem>L. innocua\u003C\u002Fem> and on June 26, 2023 confirmed that one (1) of fifty six (56) environmental swabs were positive for \u003Cem>L. innocua\u003C\u002Fem>. In 2020, FDA detected \u003Cem>L. innocua\u003C\u002Fem> in two (2) environmental swabs (sample #1127382); in 2018, FDA detected \u003Cem>L. innocua\u003C\u002Fem> in two (2) environmental swabs including a food contact surface (sample #1082411); and in 2017 FDA detected \u003Cem>L. innocua\u003C\u002Fem> in seven (7) environmental swabs (samples #1031962 and #1031963). The presence of \u003Cem>Listeria\u003C\u002Fem> species such as \u003Cem>L. innocua&nbsp;\u003C\u002Fem>suggests that conditions are suitable for survival and\u002For growth of \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>Your response to the findings included, without limitation: voluntary destruction of the lot of cheese that contacted the cutting board that tested positive; voluntarily ceased production; voluntary product recall; discarded cutting boards used directly with cheese that tested positive; cleaned and sanitized all areas that tested positive; cleaned and sanitized the entire cheese making facility including the drying room, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and brine \u003Cstrong>(b)(4)\u003C\u002Fstrong>; performed environmental swabbing; dedicated a cart for the wheels of cheese being taken from the cheese cave; changed the route to the cheese cave so that you no longer go through the production room; purchased shoe washing stations; marked the perimeter of the indoor\u002Foutdoor areas so that employees know where to change shoes and use mat washing station; stopped cutting and vacuum sealing cheese entirely; hired an employee so that you can increase scrubbing and sanitizing frequency; sought the experience of a consultant from \u003Cstrong>(b)(4)\u003C\u002Fstrong> for expertise in \u003Cem>Listeria\u003C\u002Fem> persistence.\u003C\u002Fp>\n\n\u003Cp>However, given the repeat history of positive \u003Cem>Listeria\u003C\u002Fem> findings in your processing environment and CGMP issues, we are unable to evaluate if you adequately controlled \u003Cem>L. monocytogenes\u003C\u002Fem> in your processing facility. We continue to be concerned about your ability to maintain a sanitary environment. We recommend that you continue to identify potential harborage sites and source(s) of the organism in your processing environment and implement the necessary methods and controls to ensure \u003Cem>L. monocytogenes\u003C\u002Fem> does not contaminate your environment or your RTE food products. We will verify the effectiveness of your corrective actions and your ability to maintain a sanitary environment during our next inspection.\u003C\u002Fp>\n\n\u003Cp>\u003Cu>\u003Cstrong>Current Good Manufacturing Practice (21 CFR Part 117, Subpart B):\u003C\u002Fstrong>\u003C\u002Fu>\u003C\u002Fp>\n\n\u003Cp>1. You did not clean all food-contact surfaces, including utensils and food-contact surfaces of equipment, as frequently as necessary to protect against contamination of food, as required by 21 CFR § 117.35(d). Specifically, during the inspection, investigators observed the following conditions:\u003C\u002Fp>\n\n\u003Cp>a) Old, white-yellow cheese\u002Fwax\u002Fsalt-like residues from previous lots of cheese were observed on the stainless-steel and plastic tables in your waxing\u002Fdrying room on June 21 and 26, 2023. These tables were being used to store wheels and blocks of drying cheese products. Thereafter on July 18, 2023, the same residues were observed on these tables. You stated you had cleaned and sanitized these tables three times and were unable to remove the residues, but the investigator was able to scrape off the residue from the table.\u003C\u002Fp>\n\n\u003Cp>b) Old, white cheese-like residue from the storage of previous lots of cheese was observed\u003Cbr>\non recently cleaned and sanitized wooden boards in your equipment storage area. In addition, you are storing these cleaned and sanitized boards directly on the floor in the storage area. You use these boards for aging raw milk cheese.\u003C\u002Fp>\n\n\u003Cp>Food residues may harbor and support survival and growth of pathogenic bacteria, which could result in contamination of food.\u003C\u002Fp>\n\n\u003Cp>This is a repeat deviation from FDA’s 2018 and 2020 inspections, as investigators observed then that you had not adequately cleaned and sanitized your utensils and equipment.\u003C\u002Fp>\n\n\u003Cp>Your August 11, 2023 response indicated that you consulted with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and that you “used \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaner and successfully removed deposits and strains from all tables.” You also stated that you “found that \u003Cstrong>(b)(4)\u003C\u002Fstrong> successfully removes salt deposit on aging boards. Ongoing as boards are emptied and recleaned.” In addition, in regard to the cutting boards, your response stated that you discarded all cutting boards used during the inspection and have discontinued “cut and wrap operations until procedures are determined to eliminate the chance of this happening again.” We will verify the effectiveness of your corrective actions and your ability to maintain a sanitary environment during our next inspection.\u003C\u002Fp>\n\n\u003Cp>2. You did not clean your non-food-contact surface of equipment in a manner and as frequently as necessary to protect against contamination of food, as required by 21 CFR § 117.35(e). Specifically, during the inspection, investigators observed the underside of a stainless-steel table in the manufacturing room had a heavy buildup of black-brown mold-like or rust-like residues on its surface. This table is used to store raw milk cheese products.\u003C\u002Fp>\n\n\u003Cp>Your August 11, 2023, response stated “Underside of table was hard cleaned and sanitized. \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample taken 8\u002F2\u002F23 tested negative for listeria.” However, you have not provided information as to whether or how you will ensure your corrective actions are sustained. We will verify the effectiveness of your corrective actions and your ability to maintain a sanitary environment during our next inspection.\u003C\u002Fp>\n\n\u003Cp>3. You did not maintain buildings, fixtures, and other physical facilities of your plant in a clean and sanitary condition and kept in repair adequate to prevent food from becoming adulterated, as required by 21 CFR § 117.35(a). Specifically, during the inspection, investigators observed the following conditions:\u003C\u002Fp>\n\n\u003Cp>a) Areas of black and black-brown mold-like residues on the walls and baseboards in the manufacturing room, where your products are processed. Furthermore, environmental sub #62, which was taken from the floor\u002Fwall baseboard (containing these residues) in the manufacturing room on June 26, 2023, was found positive for \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>b) Areas of black and black-brown mold-like substances on the door and around the door handle to the main cheese cave, where your products are aged. Furthermore, environmental sub #57, which was collected from this door handle on June 26, 2023, was found positive for \u003Cem>L. monocytogenes\u003C\u002Fem>. It is your practice, and what we directly observed throughout the inspection, to let employees enter and exit the main cheese cave using the door handle without wearing gloves or having to wash hands prior to entering.\u003C\u002Fp>\n\n\u003Cp>c) Areas of the floor in the manufacturing room, where your products are processed, were pitted, and had uneven and rough surfaces. Furthermore, environmental subs #61 and #91, which were taken from two different floor areas in the manufacturing room on June 26, 2023, were both found positive for \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>d) The bottom of the door, inside the main cheese cave, where your products are aged, was flaking a tape-like material. Furthermore, environmental sub #2, which was collected from this surface on June 21, 2023, was found positive for \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>e) Areas of the floor in the brine area in the main cheese cave, where your products are aged, were pitted, and had uneven and rough surfaces. Furthermore, environmental sub #9, which was collected from this surface on June 21, 2023, was found positive for \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\n\n\u003Cp>f) Buildup of water on the floor around the \u003Cstrong>(b)(4)\u003C\u002Fstrong> near the raw milk receiving room, where you intake the raw cow’s milk that is used to make your products. You stated that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> has had a “constant leak”, and that this has been an ongoing issue.\u003C\u002Fp>\n\n\u003Cp>g) Areas of black and black-brown mold-like substances and exposed foam-like insulation on the ceiling in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cheese cave, which is where your products are aged.\u003C\u002Fp>\n\n\u003Cp>h) A fan in the waxing\u002Fdrying room that was blowing on cheese product was observed to be covered with a thick layer of dust.\u003C\u002Fp>\n\n\u003Cp>Many of these are repeat observations from the 2017, 2018 and 2020 FDA inspections.\u003C\u002Fp>\n\n\u003Cp>Your August 11, 2023 response stated that you plan to replace the “stained covings the in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> and drying room” and the door handle to one that is in better condition and more cleanable. You also stated that you repaired the bottom of your brine \u003Cstrong>(b)(4)\u003C\u002Fstrong>, hard cleaned and sanitized the entire area with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and took a \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample that tested negative for \u003Cem>Listeria\u003C\u002Fem>. You also stated that you will resurface areas of the floor where pitting has occurred and repair the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cave walls and ceilings. In addition, you stated that the fan in the wax\u002Fdrying room was fully cleaned and the water leak in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> room has been repaired. Furthermore, you stated, “Seam on floor junction from brine \u003Cstrong>(b)(4)\u003C\u002Fstrong> to main cave was hard cleaned and sanitized with \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>. \u003Cstrong>(b)(4)\u003C\u002Fstrong> sample taken 7\u002F19\u002F23 tested negative for listeria.” However, you have not provided timeframes for when all corrective actions will be completed, and whether and how you will ensure the corrective actions are sustained. We will verify the effectiveness of your corrective actions and your ability to maintain a sanitary environment during our next inspection.\u003C\u002Fp>\n\n\u003Cp>4. Your equipment and utensils were not designed and were not of such material and workmanship to be adequately cleanable, and were not adequately maintained to protect against contamination, as required by 21 CFR § 117.40(a)(1). Specifically, during the inspection, investigators observed the following conditions:\u003C\u002Fp>\n\n\u003Cp>a) The rolling stand that holds your curd \u003Cstrong>(b)(4)\u003C\u002Fstrong> was observed with areas of heavy rusting and chipping paint-like material. The heavy rusting and chipped surface make the rolling stand difficult to adequately cleaned.\u003C\u002Fp>\n\n\u003Cp>b) Multiple wooden boards used for aging raw milk cheese products in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> cheese aging caves were observed to have uneven surfaces, to be rough cut, and to have knots, frays, and splinters. The knots, frays, and splinters on the uneven and rough surfaces of the boards make the boards difficult to be adequately cleaned.\u003C\u002Fp>\n\n\u003Cp>These are repeat observations from the 2017, 2018 and 2020 FDA inspections.\u003C\u002Fp>\n\n\u003Cp>Your August 11, 2023 response stated that you plan to sand and repaint the curd \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and replace the wooden boards. We will verify your corrective actions during our next inspection.\u003C\u002Fp>\n\n\u003Cp>The violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, \u003Cstrong>(b)(3)(A)\u003C\u002Fstrong> if criteria and conditions warrant.\u003C\u002Fp>\n\n\u003Cp>Please notify this office in writing within 15 working days of the receipt of this letter, as to the specific steps you have taken to address these violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as providing copies of related documentation. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time frame within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your reply to the U.S. Food and Drug Administration, Attention: Michael E. Antaya, Compliance Officer, 32 Hemingway Drive, Riverside, RI 02915 or via email (preferred) to Michael.Antaya@fda.hhs.gov. If you have questions regarding any issues in this letter, please contact Mr. Antaya at 401-528-5500 Ext 100 or Michael. Antaya@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ronald M. Pace\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Food Operations\u003Cbr>\nEast – Division 1\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Robert C. Sweitzer and Ms. Sharon Tomaselli\n\nRecipient Title\n\nCo-Owners\n\nCooperstown Cheese Company, LLC\n\n107 Oxbow Road\n\nMilford, NY 13807-1131\n\nUnited States\n\nIssuing Office:\n\nDivision of Human and Animal Food Operations East I\n\nUnited States\n\nSecondary Issuing Offices\n\nUnited States\n\nWARNING LETTER\n\nCMS # 667551\n\n11\u002F24\u002F2023\n\nDear Mr. Sweitzer and Ms. Tomaselli:\n\nThe United States Food and Drug Administration (FDA) conducted an inspection of your ready-to-eat (RTE) raw milk cheese manufacturing facility located at 107 Oxbow Road., Milford, NY 13807-1131 from June 21 through July 28, 2023. During our inspection of your facility, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food regulation (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analysis of the environmental swabs found the presence of Listeria monocytogenes (L. monocytogenes), a human pathogen, in your facility. At the conclusion of the inspection, the FDA investigators issued your facility a Form FDA 483 (FDA-483), Inspectional Observations.\n\nBased on FDA’s inspectional findings and the analytical results for samples collected from your production environment, we have determined that the RTE cheese products manufactured in your facility are adulterated within the meaning of section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)], in that they were prepared, packed or held under insanitary conditions whereby they may have become contaminated with filth or rendered injurious to health. You may find the Act and further information about the CGMP & PC rule through links in FDA’s home page at http:\u002F\u002Fwww.fda.gov.\n\nWe received your responses to FDA’s environmental sample findings via email on July 13, 17, 18, and 19, and August 3, 2023, and to the FDA-483 via email on August 11, 2023, describing corrective actions taken and planned by your firm. Based on our review of the inspectional findings and the responses that your firm provided, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\n\nPathogen Findings\n\nL. monocytogenes is a pathogenic bacterium that is widespread in the environment and may be introduced into a food processing facility from raw materials, humans, or equipment. Without proper controls, it can proliferate in food processing facilities where it may contaminate food. Therefore, it is essential to identify the areas of the food processing plant where this organism is able to grow and survive and to apply controls or take corrective actions as necessary to eradicate the organism. Consuming foods contaminated with L. monocytogenes can lead to a severe, sometimes life-threatening illness called listeriosis, which is a major public health concern due to the severity of the disease, its high case-fatality rate, its long incubation time, and its tendency to affect individuals with underlying conditions.\n\nFDA laboratory analysis of environmental sample #1221906 collected at your facility on June 21, 2023 confirmed that four (4) of fifty (50) environmental swabs were positive for L. monocytogenes, and FDA laboratory analysis of environmental sample #1228986 collected at your facility on June 26, 2023 confirmed that four (4) of fifty six (56) environmental swabs were positive for L. monocytogenes. Of the positive findings, one (1) of the L. monocytogenes positive swabs was collected from the food contact surface of a cutting board that was being used to cut RTE Jersey Girl cheese.\n\nFurthermore, dating back to 2017, your firm has had history of finished product samples that have tested positive for L. monocytogenes. In 2017, New York State Department of Agriculture and Markets (NYSDAM) collected a finished product sample of your firm’s Toma Celena cheese (lot #51017) which tested positive for L. monocytogenes. In response to this finding, your firm tested (b)(4) lots of finished products and found two additional lots (lots #52417 and #60717) to be positive for L. monocytogenes.\n\nWhole genome sequencing (WGS) was conducted on the above referenced L. monocytogenes isolates. Based on the results of the WGS analysis, the environmental swabs collected at your facility during FDA’s most recent inspection and finished product samples from 2017 represent four (4) different strains of L. monocytogenes. None of them matched any clinical isolates. We advised you of the importance of these WGS results via a conference call on July 14, 2023, and again on July 20, 2023.\n\nThe presence of L. monocytogenes in your facility and your products is significant in that it demonstrates your sanitation efforts are inadequate to effectively control pathogens in your facility to prevent contamination of food. Appropriate control of L. monocytogenes in a food processing environment requires knowledge of the unique characteristics of the organism and implementing the corresponding hygienic practices necessary to control this pathogen. Our findings indicate that your firm is neither achieving satisfactory control against the presence of L. monocytogenes within your facility nor implementing effective methods and controls to eliminate this human pathogen or minimize exposure to food and food-contact surfaces. Once it is established in a production area, personnel or equipment can facilitate the pathogen’s movement and contamination of food-contact surfaces and finished product. It is essential to identify the harborage sites in the food processing plant and equipment where this organism is able to grow and survive and to take such corrective actions as are necessary to eradicate the organism.\n\nAdditionally, FDA has repeatedly detected Listeria innocua (L. innocua), a non-pathogenic Listeria species, in environmental samples collected from your firm during the current and previous FDA inspections. FDA laboratory analysis of environmental samples collected on June 21, 2023 confirmed that three (3) of fifty (50) environmental swabs were positive for L. innocua and on June 26, 2023 confirmed that one (1) of fifty six (56) environmental swabs were positive for L. innocua. In 2020, FDA detected L. innocua in two (2) environmental swabs (sample #1127382); in 2018, FDA detected L. innocua in two (2) environmental swabs including a food contact surface (sample #1082411); and in 2017 FDA detected L. innocua in seven (7) environmental swabs (samples #1031962 and #1031963). The presence of Listeria species such as L. innocua suggests that conditions are suitable for survival and\u002For growth of L. monocytogenes.\n\nYour response to the findings included, without limitation: voluntary destruction of the lot of cheese that contacted the cutting board that tested positive; voluntarily ceased production; voluntary product recall; discarded cutting boards used directly with cheese that tested positive; cleaned and sanitized all areas that tested positive; cleaned and sanitized the entire cheese making facility including the drying room, (b)(4), and brine (b)(4); performed environmental swabbing; dedicated a cart for the wheels of cheese being taken from the cheese cave; changed the route to the cheese cave so that you no longer go through the production room; purchased shoe washing stations; marked the perimeter of the indoor\u002Foutdoor areas so that employees know where to change shoes and use mat washing station; stopped cutting and vacuum sealing cheese entirely; hired an employee so that you can increase scrubbing and sanitizing frequency; sought the experience of a consultant from (b)(4) for expertise in Listeria persistence.\n\nHowever, given the repeat history of positive Listeria findings in your processing environment and CGMP issues, we are unable to evaluate if you adequately controlled L. monocytogenes in your processing facility. We continue to be concerned about your ability to maintain a sanitary environment. We recommend that you continue to identify potential harborage sites and source(s) of the organism in your processing environment and implement the necessary methods and controls to ensure L. monocytogenes does not contaminate your environment or your RTE food products. We will verify the effectiveness of your corrective actions and your ability to maintain a sanitary environment during our next inspection.\n\nCurrent Good Manufacturing Practice (21 CFR Part 117, Subpart B):\n\n1. You did not clean all food-contact surfaces, including utensils and food-contact surfaces of equipment, as frequently as necessary to protect against contamination of food, as required by 21 CFR § 117.35(d). Specifically, during the inspection, investigators observed the following conditions:\n\na) Old, white-yellow cheese\u002Fwax\u002Fsalt-like residues from previous lots of cheese were observed on the stainless-steel and plastic tables in your waxing\u002Fdrying room on June 21 and 26, 2023. These tables were being used to store wheels and blocks of drying cheese products. Thereafter on July 18, 2023, the same residues were observed on these tables. You stated you had cleaned and sanitized these tables three times and were unable to remove the residues, but the investigator was able to scrape off the residue from the table.\n\nb) Old, white cheese-like residue from the storage of previous lots of cheese was observed\n\non recently cleaned and sanitized wooden boards in your equipment storage area. In addition, you are storing these cleaned and sanitized boards directly on the floor in the storage area. You use these boards for aging raw milk cheese.\n\nFood residues may harbor and support survival and growth of pathogenic bacteria, which could result in contamination of food.\n\nThis is a repeat deviation from FDA’s 2018 and 2020 inspections, as investigators observed then that you had not adequately cleaned and sanitized your utensils and equipment.\n\nYour August 11, 2023 response indicated that you consulted with (b)(4) and that you “used (b)(4) cleaner and successfully removed deposits and strains from all tables.” You also stated that you “found that (b)(4) successfully removes salt deposit on aging boards. Ongoing as boards are emptied and recleaned.” In addition, in regard to the cutting boards, your response stated that you discarded all cutting boards used during the inspection and have discontinued “cut and wrap operations until procedures are determined to eliminate the chance of this happening again.” We will verify the effectiveness of your corrective actions and your ability to maintain a sanitary environment during our next inspection.\n\n2. You did not clean your non-food-contact surface of equipment in a manner and as frequently as necessary to protect against contamination of food, as required by 21 CFR § 117.35(e). Specifically, during the inspection, investigators observed the underside of a stainless-steel table in the manufacturing room had a heavy buildup of black-brown mold-like or rust-like residues on its surface. This table is used to store raw milk cheese products.\n\nYour August 11, 2023, response stated “Underside of table was hard cleaned and sanitized. (b)(4) sample taken 8\u002F2\u002F23 tested negative for listeria.” However, you have not provided information as to whether or how you will ensure your corrective actions are sustained. We will verify the effectiveness of your corrective actions and your ability to maintain a sanitary environment during our next inspection.\n\n3. You did not maintain buildings, fixtures, and other physical facilities of your plant in a clean and sanitary condition and kept in repair adequate to prevent food from becoming adulterated, as required by 21 CFR § 117.35(a). Specifically, during the inspection, investigators observed the following conditions:\n\na) Areas of black and black-brown mold-like residues on the walls and baseboards in the manufacturing room, where your products are processed. Furthermore, environmental sub #62, which was taken from the floor\u002Fwall baseboard (containing these residues) in the manufacturing room on June 26, 2023, was found positive for L. monocytogenes.\n\nb) Areas of black and black-brown mold-like substances on the door and around the door handle to the main cheese cave, where your products are aged. Furthermore, environmental sub #57, which was collected from this door handle on June 26, 2023, was found positive for L. monocytogenes. It is your practice, and what we directly observed throughout the inspection, to let employees enter and exit the main cheese cave using the door handle without wearing gloves or having to wash hands prior to entering.\n\nc) Areas of the floor in the manufacturing room, where your products are processed, were pitted, and had uneven and rough surfaces. Furthermore, environmental subs #61 and #91, which were taken from two different floor areas in the manufacturing room on June 26, 2023, were both found positive for L. monocytogenes.\n\nd) The bottom of the door, inside the main cheese cave, where your products are aged, was flaking a tape-like material. Furthermore, environmental sub #2, which was collected from this surface on June 21, 2023, was found positive for L. monocytogenes.\n\ne) Areas of the floor in the brine area in the main cheese cave, where your products are aged, were pitted, and had uneven and rough surfaces. Furthermore, environmental sub #9, which was collected from this surface on June 21, 2023, was found positive for L. monocytogenes.\n\nf) Buildup of water on the floor around the (b)(4) near the raw milk receiving room, where you intake the raw cow’s milk that is used to make your products. You stated that the (b)(4) has had a “constant leak”, and that this has been an ongoing issue.\n\ng) Areas of black and black-brown mold-like substances and exposed foam-like insulation on the ceiling in the (b)(4) cheese cave, which is where your products are aged.\n\nh) A fan in the waxing\u002Fdrying room that was blowing on cheese product was observed to be covered with a thick layer of dust.\n\nMany of these are repeat observations from the 2017, 2018 and 2020 FDA inspections.\n\nYour August 11, 2023 response stated that you plan to replace the “stained covings the in the (b)(4) and drying room” and the door handle to one that is in better condition and more cleanable. You also stated that you repaired the bottom of your brine (b)(4), hard cleaned and sanitized the entire area with (b)(4) and took a (b)(4) sample that tested negative for Listeria. You also stated that you will resurface areas of the floor where pitting has occurred and repair the (b)(4) cave walls and ceilings. In addition, you stated that the fan in the wax\u002Fdrying room was fully cleaned and the water leak in the (b)(4) room has been repaired. Furthermore, you stated, “Seam on floor junction from brine (b)(4) to main cave was hard cleaned and sanitized with (b)(4) and (b)(4). (b)(4) sample taken 7\u002F19\u002F23 tested negative for listeria.” However, you have not provided timeframes for when all corrective actions will be completed, and whether and how you will ensure the corrective actions are sustained. We will verify the effectiveness of your corrective actions and your ability to maintain a sanitary environment during our next inspection.\n\n4. Your equipment and utensils were not designed and were not of such material and workmanship to be adequately cleanable, and were not adequately maintained to protect against contamination, as required by 21 CFR § 117.40(a)(1). Specifically, during the inspection, investigators observed the following conditions:\n\na) The rolling stand that holds your curd (b)(4) was observed with areas of heavy rusting and chipping paint-like material. The heavy rusting and chipped surface make the rolling stand difficult to adequately cleaned.\n\nb) Multiple wooden boards used for aging raw milk cheese products in the (b)(4) cheese aging caves were observed to have uneven surfaces, to be rough cut, and to have knots, frays, and splinters. The knots, frays, and splinters on the uneven and rough surfaces of the boards make the boards difficult to be adequately cleaned.\n\nThese are repeat observations from the 2017, 2018 and 2020 FDA inspections.\n\nYour August 11, 2023 response stated that you plan to sand and repaint the curd (b)(4), and replace the wooden boards. We will verify your corrective actions during our next inspection.\n\nThe violations cited in this letter are not intended to be an all-inclusive list of the violations that exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of the violations identified above and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure your facility complies with all requirements of federal law, including FDA regulations. This letter notifies you of our concerns and provides you an opportunity to address them. Failure to do so may result in legal action without further notice, including, without limitation, seizure, injunction, (b)(3)(A) if criteria and conditions warrant.\n\nPlease notify this office in writing within 15 working days of the receipt of this letter, as to the specific steps you have taken to address these violations, including an explanation of each step being taken to prevent the recurrence of violations, as well as providing copies of related documentation. If you cannot complete addressing these violations within 15 working days, state the reason for the delay and the time frame within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your reply to the U.S. Food and Drug Administration, Attention: Michael E. Antaya, Compliance Officer, 32 Hemingway Drive, Riverside, RI 02915 or via email (preferred) to Michael.Antaya@fda.hhs.gov. If you have questions regarding any issues in this letter, please contact Mr. Antaya at 401-528-5500 Ext 100 or Michael. Antaya@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nRonald M. Pace\n\nProgram Division Director\n\nOffice of Human and Animal Food Operations\n\nEast – Division 1","Cooperstown Cheese Company, LLC","cooperstown-cheese-company-llc-667551-11242023","2026-08-18T06:42:28.994808+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcooperstown-cheese-company-llc-667551-11242023","2026-10-26T08:08:18.09945+00:00","2023-12-26","667551","Division of Human and Animal Food Operations East I","Mr. Robert C. Sweitzer and Ms. Sharon Tomaselli","2026-08-20T00:24:19.543+00:00","VIA UNITED PARCEL SERVICE","2023-11-24",{"id":155,"raw":156,"subject":38,"body_html":158,"body_text":159,"firm_name":160,"letter_id":161,"created_at":76,"fei_number":19,"letter_url":162,"updated_at":163,"action_type":22,"case_status":23,"posted_date":79,"marcs_cms_no":164,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":81,"body_fetched_at":165,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":79,"medical_device_id":19,"response_letter_date":19},3181,[69,70,157,37,38,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcool-vapes-cranberry-616905-08262021\">Cool Vapes Cranberry\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Richard Marino\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cool Vapes Cranberry\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>20232 Perry Highway, Unit 1\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Cranberry Township\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>16066\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rj@coolvapes.com\"> rj@coolvapes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Marino:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Cool Vapes, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Cool Vapes Irish Cream 30ml 0.3% e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 19,500 products listed with FDA.\u003C\u002Fp>\n\n\u003Cp>It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them.\u003C\u002Fp>\n\n\u003Cp>You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100197 in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003Cbr>\n\u003Cbr>\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nRichard Marino\n\nRecipient Title\n\nOwner\n\nCool Vapes Cranberry\n\n20232 Perry Highway, Unit 1\n\nCranberry Township, PA 16066\n\nUnited States\n\nrj@coolvapes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Marino:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records, and determined that Cool Vapes, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)) these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1. Therefore, these products are required to be in compliance with the requirements in the FD&C Act.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have a premarket authorization in effect. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Cool Vapes Irish Cream 30ml 0.3% e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 19,500 products listed with FDA.\n\nIt is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above, and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your actions to address any violations and bring your products into compliance, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them.\n\nYou can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100197 in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Cool Vapes Cranberry","cool-vapes-cranberry-616905-08262021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcool-vapes-cranberry-616905-08262021","2026-10-26T08:08:17.893186+00:00","616905","2026-08-20T02:39:36.284+00:00",{"id":167,"raw":168,"subject":38,"body_html":170,"body_text":171,"firm_name":172,"letter_id":173,"created_at":76,"fei_number":19,"letter_url":174,"updated_at":175,"action_type":22,"case_status":23,"posted_date":79,"marcs_cms_no":176,"product_type":48,"closeout_date":19,"issuing_office":37,"recipient_name":81,"body_fetched_at":177,"delivery_method":50,"recipient_title":19,"reference_number":19,"action_taken_date":79,"medical_device_id":19,"response_letter_date":19},3180,[69,70,169,37,38,13,13,13],"\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcool-vapes-allison-park-616761-08262021\">Cool Vapes Allison Park\u003C\u002Fa>","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UPS and Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Tobacco                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Richard Marino\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Owner\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Cool Vapes Allison Park\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>4960 Route 8\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Allison Park\u003C\u002Fspan>, \u003Cspan>PA\u003C\u002Fspan> \u003Cspan>15101\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:rj@coolvapes.com\"> rj@coolvapes.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Tobacco Products\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Marino:\u003C\u002Fp>\n\n\u003Cp>The Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records and determined that Cool Vapes, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\u003C\u002Fp>\n\n\u003Cp>Under section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&amp;C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1.\u003C\u002Fp>\n\n\u003Cp>Please be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&amp;C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at \u003Ca href=\"https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\">https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685\u003C\u002Fa>.\u003C\u002Fp>\n\n\u003Cp>The FD&amp;C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&amp;C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&amp;C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&amp;C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&amp;C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&amp;C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&amp;C Act (21 U.S.C. § 387e(j)(3)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>A New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>FDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Cool Vapes Looper 30ml 0.3% e-liquid product without a marketing authorization order.\u003C\u002Fp>\n\n\u003Cp>The tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&amp;C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&amp;C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&amp;C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&amp;C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&amp;C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&amp;C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&amp;C Act (21 U.S.C. § 331(p)).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion and Requested Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>Your firm is a registered manufacturer with over 19,400 products listed with FDA. It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&amp;C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&amp;C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\u003C\u002Fp>\n\n\u003Cp>The violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above and take any necessary actions to bring your tobacco products into compliance with the FD&amp;C Act.\u003C\u002Fp>\n\n\u003Cp>Please submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&amp;C Act. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>Please note your reference number, ER2100201, in your response and direct your response to the following address:\u003C\u002Fp>\n\n\u003Cp>DEM-WL Response, Office of Compliance and Enforcement\u003Cbr>\nFDA Center for Tobacco Products\u003Cbr>\nc\u002Fo Document Control Center\u003Cbr>\nBuilding 71, Room G335\u003Cbr>\n10903 New Hampshire Avenue\u003Cbr>\nSilver Spring, MD 20993-0002\u003C\u002Fp>\n\n\u003Cp>If you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann Simoneau, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance and Enforcement\u003Cbr>\nCenter for Tobacco Products\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UPS and Electronic Mail\n\nProduct:\n\nTobacco\n\nRecipient:\n\nRecipient Name\n\nRichard Marino\n\nRecipient Title\n\nOwner\n\nCool Vapes Allison Park\n\n4960 Route 8\n\nAllison Park, PA 15101\n\nUnited States\n\nrj@coolvapes.com\n\nIssuing Office:\n\nCenter for Tobacco Products\n\nUnited States\n\nWARNING LETTER\n\nDear Mr. Marino:\n\nThe Center for Tobacco Products of the U.S. Food and Drug Administration (FDA) has reviewed your submissions to the FDA and our inspection records and determined that Cool Vapes, LLC manufactures and distributes e-liquid products for commercial distribution in the United States, and that the e-liquid products are manufactured and offered for sale or distribution to customers in the United States.\n\nUnder section 201(rr) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) (21 U.S.C. § 321(rr)), these products are tobacco products because they are made or derived from tobacco and intended for human consumption. Certain tobacco products, including e-liquid products, are subject to FDA jurisdiction under section 901(b) of the FD&C Act (21 U.S.C. § 387a(b)) and 21 C.F.R. § 1100.1.\n\nPlease be aware that, effective August 8, 2016, FDA deemed additional products meeting the definition of a tobacco product, except accessories to these newly deemed products, to be subject to regulation under the FD&C Act. These products include, but are not limited to, electronic nicotine delivery systems (including e-cigarettes and e-liquids), cigars, and pipe tobacco. See Final Rule, Deeming Tobacco Products To Be Subject to the Federal Food, Drug, and Cosmetic Act, as Amended by the Family Smoking Prevention and Tobacco Control Act; Restrictions on the Sale and Distribution of Tobacco Products and Required Warning Statements for Tobacco Products, 81 Fed. Reg. 28,974 (May 10, 2016), available at https:\u002F\u002Ffederalregister.gov\u002Fa\u002F2016-10685.\n\nThe FD&C Act requires “new tobacco products” to have premarket authorization. A “new tobacco product” is any tobacco product that was not commercially marketed in the United States as of February 15, 2007, or any modified tobacco product that was commercially marketed after February 15, 2007 (section 910(a) of the FD&C Act; 21 U.S.C. § 387j(a)). Generally, a marketing authorization order under section 910(c)(1)(A)(i) of the FD&C Act (21 U.S.C. § 387j(c)(1)(A)(i)) is required for a new tobacco product unless (1) the manufacturer of the product submitted a report under section 905(j) of the FD&C Act (21 U.S.C. § 387e(j)) and FDA issues an order finding the product substantially equivalent to a predicate tobacco product (section 910(a)(2)(A) of the FD&C Act) or (2) the manufacturer submitted a report under section 905(j)(1)(A)(ii) of the FD&C Act (21 U.S.C. § 387e(j)(1)(A)(ii)) and all modifications are covered by exemptions from the requirements of substantial equivalence granted by FDA under section 905(j)(3) of the FD&C Act (21 U.S.C. § 387e(j)(3)).\n\nA New Tobacco Product Without Required Marketing Authorization Is Adulterated and Misbranded\n\nFDA has determined that you manufacture, sell, and\u002For distribute to customers in the United States Cool Vapes Looper 30ml 0.3% e-liquid product without a marketing authorization order.\n\nThe tobacco product listed above is a new tobacco product because it was not commercially marketed in the United States as of February 15, 2007. This product does not have an FDA marketing authorization order in effect under section 910(c)(1)(A)(i) of the FD&C Act and is not otherwise exempt from the marketing authorization requirement. Therefore, this product is adulterated under section 902(6)(A) of the FD&C Act (21 U.S.C. § 387b(6)(A)). In addition, it is misbranded under section 903(a)(6) of the FD&C Act (21 U.S.C. § 387c(a)(6)) because a notice or other information respecting this product was not provided as required by section 905(j) of the FD&C Act. The doing of any act with respect to a tobacco product while such article is held for sale after shipment in interstate commerce which results in such product being adulterated or misbranded is a prohibited act under section 301(k) of the FD&C Act (21 U.S.C. § 331(k)). Additionally, to the extent that a report was required under section 905(j) of the FD&C Act, the failure to provide such report is a prohibited act under section 301(p) of the FD&C Act (21 U.S.C. § 331(p)).\n\nConclusion and Requested Actions\n\nYour firm is a registered manufacturer with over 19,400 products listed with FDA. It is your responsibility to ensure that all of your tobacco products comply with each applicable provision of the FD&C Act and FDA’s implementing regulations. Failure to adequately address this matter may lead to regulatory action, including, but not limited to, civil money penalties, seizure, and\u002For injunction. However, this Warning Letter does not constitute “written notice” for purposes of section 303(f)(9)(B)(i)(II) of the FD&C Act. Please note that tobacco products offered for import into the United States that appear to be adulterated and\u002For misbranded may be detained or refused admission.\n\nThe violations discussed in this letter do not necessarily constitute an exhaustive list. You should take prompt action to address any violations that are referenced above, as well as violations that are the same as or similar to the ones stated above and take any necessary actions to bring your tobacco products into compliance with the FD&C Act.\n\nPlease submit a written response to this letter within 15 working days from the date of receipt describing your corrective actions, including the dates on which you discontinued the violative sale, and\u002For distribution of these tobacco products and your plan for maintaining compliance with the FD&C Act. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration. This letter notifies you of our findings and provides you with an opportunity to address them. You can find the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nPlease note your reference number, ER2100201, in your response and direct your response to the following address:\n\nDEM-WL Response, Office of Compliance and Enforcement\n\nFDA Center for Tobacco Products\n\nc\u002Fo Document Control Center\n\nBuilding 71, Room G335\n\n10903 New Hampshire Avenue\n\nSilver Spring, MD 20993-0002\n\nIf you have any questions about the content of this letter, please contact Lillian Ortega at (240) 402-9041 or Lillian.Ortega@fda.hhs.gov.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn Simoneau, J.D.\n\nDirector\n\nOffice of Compliance and Enforcement\n\nCenter for Tobacco Products","Cool Vapes Allison Park","cool-vapes-allison-park-616761-08262021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcool-vapes-allison-park-616761-08262021","2026-10-26T08:08:17.850287+00:00","616761","2026-08-20T02:39:30.997+00:00",{"id":179,"raw":180,"subject":186,"body_html":187,"body_text":188,"firm_name":189,"letter_id":190,"created_at":18,"fei_number":19,"letter_url":191,"updated_at":192,"action_type":22,"case_status":23,"posted_date":193,"marcs_cms_no":194,"product_type":26,"closeout_date":19,"issuing_office":184,"recipient_name":195,"body_fetched_at":196,"delivery_method":197,"recipient_title":19,"reference_number":19,"action_taken_date":198,"medical_device_id":19,"response_letter_date":19},1455,[181,182,183,184,185,13,13,13],"\u003Ctime datetime=\"2024-05-14T13:20:00Z\">05\u002F14\u002F2024\u003C\u002Ftime>\n","\u003Ctime datetime=\"2024-03-29T04:00:00Z\">03\u002F29\u002F2024\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcoombe-castle-international-ltd-678304-03292024\">Coombe Castle International Ltd.\u003C\u002Fa>","Center for Food Safety and Applied Nutrition (CFSAN)","Low Acid Canned Food Regulation\u002FAdulterated \u003Cbr \u002F>\r\n","Low Acid Canned Food Regulation\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>Via Express Delivery\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Peter Mitchell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Operations Director\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Coombe Castle International Ltd.\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>1 Ingodmells Courtedinburgh Way\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Melksham, Wiltshire\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>SN12 8FH\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United Kingdom\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Center for Food Safety and Applied Nutrition (CFSAN)\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003Cbr>\nReference #: CMS 678304\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Mitchell,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your low-acid canned food (LACF) facility, located at The Creamery, Western Way, Melksham, Wiltshire, United Kingdom on October 30 &amp; 31, 2023. The inspection revealed serious violations of the Emergency Permit Control regulation [Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108)] and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation [Title 21, Code of Federal Regulations, Part 113 (21 CFR 113)]. At the conclusion of the inspection, an FDA-483, Inspectional Observations, was issued listing the serious deviations found at your firm. We acknowledge receipt of your responses, received via email on November 15, 2023, December 29, 2023, and February 1, 2024, which included corrective actions and supporting documentation taken by your firm in response to the observations noted on the FDA-483. Our evaluation of the documentation provided in your responses revealed that your responses were not adequate, as further described in this letter.\u003C\u002Fp>\n\n\u003Cp>As a manufacturer of LACF food products intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the Federal regulations relating to the processing of LACF foods. As outlined in the regulations, a commercial processor of LACF foods that does not adhere to all of the mandatory requirements of 21 CFR 108.35 and 21 CFR 113 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344). As stated in 21 CFR 108.35, for imported products, in lieu of issuing an order of determination that a permit is required before products from such commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violations of the mandatory requirements set forth in 21 CFR 108.35 and 21 CFR 113 renders your LACF CLOTTED CREAM products adulterated within the meaning of section 402(a)(4) of the Act (21 U.S.C. 342(a)(4)) in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health. You can find the Act and the LACF regulations through links in FDA's home page at www.fda.gov.\u003C\u002Fp>\n\n\u003Cp>Your significant violations are as follows:\u003C\u002Fp>\n\n\u003Cp>1. As a commercial processor engaged in the \u003Cstrong>(b)(4)\u003C\u002Fstrong> processing of low-acid foods packaged in hermetically sealed containers, you must process each low-acid food in each container size in conformity with at least the scheduled process, as required by 21 CFR 108.35 (c)(3)(i). Specifically, our investigator reviewed your scheduled processes for your 1 oz. (28 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) and 6 oz. (170 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) products, and noted the following deviations:\u003Cbr>\na. The scheduled process for your 1 oz. (28 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) product identifies a process time of \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes at a processing temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F). However, on October 30, 2023, Lot #3303A was processed for \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C, \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes below the time listed on your filed schedule process.\u003C\u002Fp>\n\n\u003Cp>b. The scheduled process for your 6 oz. (170 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) product identifies a process time of \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes and at a processing temperature of \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong> °F). However, you informed our investigator that you process CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) packaged in 85g, 160g, and 170g glass jars for \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C (\u003Cstrong>(b)(4)\u003C\u002Fstrong>°F), which is 4 degrees lower than the temperature listed on your filed schedule process.\u003C\u002Fp>\n\n\u003Cp>These changes to your scheduled processes were made without the consultation of a process authority, nor did you file with the FDA an intentional change to your process schedules.\u003C\u002Fp>\n\n\u003Cp>In your response email, dated December 29, 2023, you provided a Process Authority Report for your 6 oz. (170 g) and 1 oz. (28 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) products, which you identified as a corrective action in your February 1, 2024, email. The email also described that you have increased the duration of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> phases of your processes and reduced the duration of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> phase by the same amount, and also provided master manufacturing records identifying updated manufacturing parameters including a hold time of \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C for your 85 g, 160 g, and 170 g products, and a hold time of \u003Cstrong>(b)(4)\u003C\u002Fstrong> minutes at \u003Cstrong>(b)(4)\u003C\u002Fstrong>°C for your 28 g product. As required by 21 CFR 108.35(c)(2)(ii), if a packer intentionally makes a change in a previously filed scheduled process by reducing the initial temperature or retort temperature, reducing the time of processing, or changing the product formulation, the container, or any other condition basic to the adequacy of scheduled process, he shall prior to using such changed process obtain substantiation by qualified scientific authority as to its adequacy and notify the agency accordingly. To date, we have not received any new filings with the FDA for these products, or any requests to change your currently filed scheduled processes.\u003C\u002Fp>\n\n\u003Cp>In addition to your Process Authority Report which summarizes validation studies undertaken by your firm regarding your 6 oz. (170 g) and 1 oz. (28 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) products, you also attest in your February 1, 2024, email, that products received a process that renders them free of microorganisms, are therefore commercially sterile, and provide finished product testing results. However, your Process Authority Report did not demonstrate that products, as observed during the inspection, had been given a \u003Cstrong>(b)(4)\u003C\u002Fstrong> process that rendered them free of microorganisms of potential public health significance. Nor is it clear in your emailed responses, if product(s) were held pending review by your Process Authority, reprocessed according to parameters identified in your scheduled processes, or destroyed, as applicable, and as required by 21 CFR 113.89.\u003C\u002Fp>\n\n\u003Cp>This letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the Emergency Permit Control regulation [Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108)], the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation (21 CFR Part 113), and the current Good Manufacturing Practice regulation (21 CFR Part 117).\u003C\u002Fp>\n\n\u003Cp>You should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these violations. More specifically, your response should include documentation and information that would assist us in evaluating your corrections, including processing records for five lots of product produced over at least five days. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>If you do not respond, or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported LACF food products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA's Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with LACF food regulations (21 CFR 108 and 113), is Import Alert #99-38, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods Due to Inadequate Process Controls. This alert can be found on FDA's web site at https:\u002F\u002Fwww.accessdata.fda.gov\u002FCMS_IA\u002Fimportalert_1132.html.\u003Cbr>\n\u003Cbr>\nPlease send your reply to the Food and Drug Administration, Attention: Amy R. Glynn, Compliance Officer, Food Adulteration Assessment Branch, Office of Compliance, Division of Enforcement, 5001 Campus Drive, College Park, MD 20740 U.S.A., or send via email at amy.glynn@fda.hhs.gov. Please reference CMS # 678304 on any submissions and within the subject line of any emails to us.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>Ann M. Oxenham, J.D.\u003Cbr>\nDirector\u003Cbr>\nOffice of Compliance\u003Cbr>\nCenter for Food Safety\u003Cbr>\n&nbsp; &nbsp; and Applied Nutrition\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVia Express Delivery\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nPeter Mitchell\n\nRecipient Title\n\nOperations Director\n\nCoombe Castle International Ltd.\n\n1 Ingodmells Courtedinburgh Way\n\nMelksham, Wiltshire\n\nSN12 8FH\n\nUnited Kingdom\n\nIssuing Office:\n\nCenter for Food Safety and Applied Nutrition (CFSAN)\n\nUnited States\n\nWARNING LETTER\n\nReference #: CMS 678304\n\nDear Mr. Mitchell,\n\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your low-acid canned food (LACF) facility, located at The Creamery, Western Way, Melksham, Wiltshire, United Kingdom on October 30 & 31, 2023. The inspection revealed serious violations of the Emergency Permit Control regulation [Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108)] and the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation [Title 21, Code of Federal Regulations, Part 113 (21 CFR 113)]. At the conclusion of the inspection, an FDA-483, Inspectional Observations, was issued listing the serious deviations found at your firm. We acknowledge receipt of your responses, received via email on November 15, 2023, December 29, 2023, and February 1, 2024, which included corrective actions and supporting documentation taken by your firm in response to the observations noted on the FDA-483. Our evaluation of the documentation provided in your responses revealed that your responses were not adequate, as further described in this letter.\n\nAs a manufacturer of LACF food products intended for export to the United States, you are required to comply with the Federal Food Drug and Cosmetic Act (the Act) and the Federal regulations relating to the processing of LACF foods. As outlined in the regulations, a commercial processor of LACF foods that does not adhere to all of the mandatory requirements of 21 CFR 108.35 and 21 CFR 113 could be subjected to an immediate application of the emergency permit control provisions of section 404 of the Act (21 U.S.C. 344). As stated in 21 CFR 108.35, for imported products, in lieu of issuing an order of determination that a permit is required before products from such commercial processor can be introduced into interstate commerce, FDA may take steps to refuse admission of the commercial processor's products under section 801 of the Act (21 U.S.C. 381) when offered for entry into the United States. Violations of the mandatory requirements set forth in 21 CFR 108.35 and 21 CFR 113 renders your LACF CLOTTED CREAM products adulterated within the meaning of section 402(a)(4) of the Act (21 U.S.C. 342(a)(4)) in that they have been prepared, packed, or held under insanitary conditions whereby they may have been rendered injurious to health. You can find the Act and the LACF regulations through links in FDA's home page at www.fda.gov.\n\nYour significant violations are as follows:\n\n1. As a commercial processor engaged in the (b)(4) processing of low-acid foods packaged in hermetically sealed containers, you must process each low-acid food in each container size in conformity with at least the scheduled process, as required by 21 CFR 108.35 (c)(3)(i). Specifically, our investigator reviewed your scheduled processes for your 1 oz. (28 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) and 6 oz. (170 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) products, and noted the following deviations:\n\na. The scheduled process for your 1 oz. (28 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) product identifies a process time of (b)(4) minutes at a processing temperature of (b)(4)°C ((b)(4)°F). However, on October 30, 2023, Lot #3303A was processed for (b)(4) minutes at (b)(4)°C, (b)(4) minutes below the time listed on your filed schedule process.\n\nb. The scheduled process for your 6 oz. (170 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) product identifies a process time of (b)(4) minutes and at a processing temperature of (b)(4)°C ((b)(4) °F). However, you informed our investigator that you process CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) packaged in 85g, 160g, and 170g glass jars for (b)(4) minutes at (b)(4)°C ((b)(4)°F), which is 4 degrees lower than the temperature listed on your filed schedule process.\n\nThese changes to your scheduled processes were made without the consultation of a process authority, nor did you file with the FDA an intentional change to your process schedules.\n\nIn your response email, dated December 29, 2023, you provided a Process Authority Report for your 6 oz. (170 g) and 1 oz. (28 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) products, which you identified as a corrective action in your February 1, 2024, email. The email also described that you have increased the duration of the (b)(4) phases of your processes and reduced the duration of the (b)(4) phase by the same amount, and also provided master manufacturing records identifying updated manufacturing parameters including a hold time of (b)(4) minutes at (b)(4)°C for your 85 g, 160 g, and 170 g products, and a hold time of (b)(4) minutes at (b)(4)°C for your 28 g product. As required by 21 CFR 108.35(c)(2)(ii), if a packer intentionally makes a change in a previously filed scheduled process by reducing the initial temperature or retort temperature, reducing the time of processing, or changing the product formulation, the container, or any other condition basic to the adequacy of scheduled process, he shall prior to using such changed process obtain substantiation by qualified scientific authority as to its adequacy and notify the agency accordingly. To date, we have not received any new filings with the FDA for these products, or any requests to change your currently filed scheduled processes.\n\nIn addition to your Process Authority Report which summarizes validation studies undertaken by your firm regarding your 6 oz. (170 g) and 1 oz. (28 g) CLOTTED CREAM (HEAVY CREAM) (55% MILKFAT) products, you also attest in your February 1, 2024, email, that products received a process that renders them free of microorganisms, are therefore commercially sterile, and provide finished product testing results. However, your Process Authority Report did not demonstrate that products, as observed during the inspection, had been given a (b)(4) process that rendered them free of microorganisms of potential public health significance. Nor is it clear in your emailed responses, if product(s) were held pending review by your Process Authority, reprocessed according to parameters identified in your scheduled processes, or destroyed, as applicable, and as required by 21 CFR 113.89.\n\nThis letter may not list all the deviations at your facility. You are responsible for ensuring that your processing plant operates in compliance with the Act and all applicable regulations, including the Emergency Permit Control regulation [Title 21, Code of Federal Regulations, Part 108 (21 CFR Part 108)], the Thermally Processed Low-Acid Foods Packaged in Hermetically Sealed Containers regulation (21 CFR Part 113), and the current Good Manufacturing Practice regulation (21 CFR Part 117).\n\nYou should respond in writing within fifteen (15) working days from your receipt of this letter. Your response should outline the specific things you are doing to correct these violations. More specifically, your response should include documentation and information that would assist us in evaluating your corrections, including processing records for five lots of product produced over at least five days. If you cannot complete all corrections within 15 days, you should explain the reason for your delay and state when you will correct any remaining violations. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\n\nIf you do not respond, or if we find your response inadequate, we may take further action. For instance, we may take further action to refuse admission of your imported LACF food products under section 801(a) of the Act (21 U.S.C. § 381(a)), including placing them on detention without physical examination (DWPE). FDA's DWPE is an administrative procedure whereby products offered for import into the United States may be detained without physical examination upon entry. DWPE information may be conveyed in FDA's Import Alerts. For your information, an example of an Import Alert that conveys information specific to foreign firms that are not in compliance with LACF food regulations (21 CFR 108 and 113), is Import Alert #99-38, Detention without Physical Examination of Low-Acid Canned Foods and Acidified Foods Due to Inadequate Process Controls. This alert can be found on FDA's web site at https:\u002F\u002Fwww.accessdata.fda.gov\u002FCMS_IA\u002Fimportalert_1132.html.\n\nPlease send your reply to the Food and Drug Administration, Attention: Amy R. Glynn, Compliance Officer, Food Adulteration Assessment Branch, Office of Compliance, Division of Enforcement, 5001 Campus Drive, College Park, MD 20740 U.S.A., or send via email at amy.glynn@fda.hhs.gov. Please reference CMS # 678304 on any submissions and within the subject line of any emails to us.\n\nSincerely,\n\n\u002FS\u002F\n\nAnn M. Oxenham, J.D.\n\nDirector\n\nOffice of Compliance\n\nCenter for Food Safety\n\nand Applied Nutrition","Coombe Castle International Ltd.","coombe-castle-international-ltd-678304-03292024","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fcoombe-castle-international-ltd-678304-03292024","2026-10-26T08:08:17.962153+00:00","2024-05-14","678304","Peter Mitchell","2026-08-20T00:05:28.05+00:00","Via Express Delivery","2024-03-29",{"id":200,"raw":201,"subject":206,"body_html":207,"body_text":208,"firm_name":209,"letter_id":210,"created_at":211,"fei_number":19,"letter_url":212,"updated_at":213,"action_type":22,"case_status":23,"posted_date":214,"marcs_cms_no":215,"product_type":26,"closeout_date":19,"issuing_office":205,"recipient_name":216,"body_fetched_at":217,"delivery_method":218,"recipient_title":19,"reference_number":19,"action_taken_date":219,"medical_device_id":19,"response_letter_date":19},21713,[202,203,204,205,206,13,13,13],"\u003Ctime datetime=\"2026-09-29T04:00:00Z\">09\u002F29\u002F2026\u003C\u002Ftime>\n","\u003Ctime datetime=\"2026-03-06T05:00:00Z\">03\u002F06\u002F2026\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiddlefield-original-cheese-cooperative-719761-03062026\">Middlefield Original Cheese Cooperative\u003C\u002Fa>","Human Foods Program","CGMP\u002FManufacturing, Packing or Holding Human Food\u002FAdulterated\u002FInsanitary Conditions","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA Electronic Mail\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Food &amp; Beverages                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Mr. Nevin R. Byler\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Middlefield Original Cheese Cooperative\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>16942 Kinsman Rd\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Middlefield\u003C\u002Fspan>, \u003Cspan>OH\u003C\u002Fspan> \u003Cspan>44062\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n            \n            \u003Cdd>\n\n    \u003C\u002Fdd>\u003Cdd>\u003Cspan>\u003C\u002Fspan>\u003Ca href=\"mailto:Sunrisecreamery@plainconnect.com\"> Sunrisecreamery@plainconnect.com\u003C\u002Fa>\u003C\u002Fdd>\n\n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Human Foods Program\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>March 6, 2026\u003C\u002Fp>\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>Re: CMS # 719761\u003C\u002Fp>\u003Cp>Dear Mr. Byler:\u003C\u002Fp>\u003Cp>The United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) human food manufacturing facility, located at 16942 Kinsman Rd Middlefield, OH 44062 on August 12, 2025, through September 8, 2025. This inspection was initiated as a follow-up to a voluntary recall your firm conducted of cheese products due to your findings of pathogenic \u003Cem>Listeria monocytogenes (L. monocytogenes)\u003C\u002Fem> in cheese manufactured by your facility.\u003C\u002Fp>\u003Cp>During the inspection of your facility, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food Regulations (CGMP &amp; PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analyses of the environmental swabs found the presences of \u003Cem>L. monocytogenes\u003C\u002Fem>, a human pathogen, in your facility.\u003C\u002Fp>\u003Cp>Based on FDA’s inspectional findings and analytical results for samples collected from your production environment, we have determined that the RTE cheese products manufactured in your facility are adulterated within the meaning section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP &amp; PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and FDA’s regulations through links on FDA’s homepage at www.fda.gov.\u003C\u002Fp>\u003Cp>At the conclusion of the inspection, FDA issued an FDA Form 483 (FDA-483), Inspectional Observations, listing deviations found at your facility. On September 17, 2025, we received your firm’s responses to the FDA-483 via email, describing corrective actions taken and planned by your firm. Based on our review of the inspectional findings and the responses that you provided, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\u003Cbr>We discuss your responses below.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Hazard Analysis and Risk-Based Preventive Controls Requirements (21 CFR Part 117, Subpart C)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>1. You did not implement preventive controls in your food safety plan to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act, as required by 21 CFR 117.135(a)(1).\u003C\u002Fp>\u003Cp>Specifically, your hazard analysis for your various cheese products identifies the hazard of contamination with environmental pathogens such as “Bacterial Pathogens” such as Listeria, \u003Cstrong>(b)(4)\u003C\u002Fstrong>. Salmonella, \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and\u002For \u003Cstrong>(b)(4)\u003C\u002Fstrong> as requiring a preventive control at the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” and the “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” steps. Your sanitation preventive controls indicate that environmental monitoring is to be performed \u003Cstrong>(b)(4)\u003C\u002Fstrong>, sanitizer chemical concentrations are to be tested \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> inspections are to be performed \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, FDA Investigators observed the following instances in which you failed to implement your procedures:\u003C\u002Fp>\u003Cp>a. A review of your records revealed that you had not conducted environmental monitoring during the \u003Cstrong>(b)(4)\u003C\u002Fstrong> of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This is a repeat deviation from the previous FDA inspection conducted on September 18, 2023 through September 27, 2023 during which it was observed you did not implement \u003Cstrong>(b)(4)\u003C\u002Fstrong> environmental monitoring activities as required by your environmental monitoring program.\u003C\u002Fp>\u003Cp>b. A review of your records revealed that you failed to test the concentration of your \u003Cstrong>(b)(4) \u003C\u002Fstrong>sanitizer during the \u003Cstrong>(b)(4)\u003C\u002Fstrong>. This \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitizer is used \u003Cstrong>(b)(4)\u003C\u002Fstrong> to sanitize your cheese processing equipment \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Furthermore, preventive controls are subject to preventive control management components (monitoring, corrective actions and corrections, and verification) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility’s food safety system (see 21 CFR 117.140). We note that you did not have adequate controls in place for contamination with environmental pathogens regarding monitoring, corrective action and verification activities, as evidenced by the following observations during the inspection:\u003C\u002Fp>\u003Cp>c. A review of your environmental monitoring records revealed positive findings of \u003Cem>L. monocytogenes\u003C\u002Fem> in your facility on \u003Cstrong>(b)(4)\u003C\u002Fstrong> and again in repeat locations beginning on \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong>. The repeat positive findings collected from the same locations indicate that your current corrective action strategy of cleaning, sanitizing, and re-swabbing until achieving negative results is inadequate for controlling environmental pathogens in your facility.\u003C\u002Fp>\u003Cp>d. FDA Investigators collected an environmental sample from your facility on August 12, 2025 during the manufacturing of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cheese. The sample consisted of 80 environmental swabs collected from various surfaces in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> room, which resulted in the finding of 14 positive swabs for \u003Cem>L. monocytogenes\u003C\u002Fem>.\u003C\u002Fp>\u003Cp>e. Your written environmental monitoring program, dated January 9, 2023, specifies the “corrective action for environmental monitoring positive listeria” for “Zone \u003Cstrong>(b)(4)\u003C\u002Fstrong>” is to “…Clean equipment and resample for Listeria…”, “…Reclean and resample until negative sample” and “Conduct retraining for employee Sanitation.” However, your environmental monitoring program is inadequate because it does not include a procedure for determining the root cause of contamination and does not address product disposition after a positive result is reported, as required by 21 CFR 117.150(a)(2).\u003C\u002Fp>\u003Cp>f. The FDA investigators observed equipment in your \u003Cstrong>(b)(4)\u003C\u002Fstrong> room which lacked an adequately cleanable design which creates a food contamination risk. Specifically, the metal surfaces surrounding the underside of the \u003Cstrong>(b)(4)\u003C\u002Fstrong> were corroded and pieces of metal flaked off upon touching the surface.\u003C\u002Fp>\u003Cp>Your September 17, 2025 response identified the root cause of the \u003Cem>L. monocytogenes\u003C\u002Fem> finding in the plant as “…\u003Cstrong>(b)(4)\u003C\u002Fstrong>…” and “…\u003Cstrong>(b)(4)\u003C\u002Fstrong>…” and states that you took the corrective actions of \u003Cstrong>(b)(4)\u003C\u002Fstrong>. However, your response does not identify the source of the \u003Cem>L. monocytogenes\u003C\u002Fem> or include any evidence that an investigation was conducted to determine the source of contamination. Your response also does not include evidence to demonstrate that the referenced actions have been completed such as the updated environmental monitoring program, cleaning\u002Fsanitation procedures, corresponding monitoring records, and photographic evidence or a detailed description of what was cleaned and sanitized and how the tasks were completed to demonstrate the facility and equipment repairs were made. Furthermore, your response included a laboratory report, dated \u003Cstrong>(b)(4)\u003C\u002Fstrong>, capturing environmental monitoring results for \u003Cstrong>(b)(4)\u003C\u002Fstrong> swab sub-samples collected on \u003Cstrong>(b)(4)\u003C\u002Fstrong>. One collection of \u003Cstrong>(b)(4) \u003C\u002Fstrong>environmental swabs is not representative of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> square foot facility as it does not provide adequate assurance that the \u003Cem>L. monocytogenes\u003C\u002Fem> found in your facility has been eliminated from the processing environment based on the severity of the findings in the environment and in finished product.\u003C\u002Fp>\u003Cp>2. You did not review your process preventive control monitoring and verification records, as required by 21 CFR 117.165(a)(4).\u003C\u002Fp>\u003Cp>Specifically:\u003Cbr>a. From January 2025 through July 2025, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> sanitation forms for the \u003Cstrong>(b)(4) \u003C\u002Fstrong>production room, plant packaging area, and \u003Cstrong>(b)(4)\u003C\u002Fstrong> room repeatedly lacked a signature, or included a signature with no date, to indicate who reviewed the records and when.\u003C\u002Fp>\u003Cp>b. From \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong> your \u003Cstrong>(b)(4)\u003C\u002Fstrong> cleaning log lacked dates for record review.\u003C\u002Fp>\u003Cp>c. From April 2025 through August 2025, your \u003Cstrong>(b)(4)\u003C\u002Fstrong> “chemical concentration logs” lacked signatures capturing review. Your chemical concentration logs capture concentrations for detergents and sanitizers used for cleaning and sanitizing the manufacturing environment and equipment.\u003C\u002Fp>\u003Cp>d. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> test results for January 2, 2025, through August 19, 2025, lacked signatures or dates to indicate the results were reviewed. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> records capture the testing for the presence of antibiotic residues for your incoming raw milk.\u003C\u002Fp>\u003Cp>e. Your \u003Cstrong>(b)(4)\u003C\u002Fstrong> pasteurizer time and temperature monitoring charts contained review signatures but lacked review dates for charts dated \u003Cstrong>(b)(4) \u003C\u002Fstrong>and \u003Cstrong>(b)(4)\u003C\u002Fstrong> and \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>f. Your metal detector verification log lacked signatures or dates to indicate the logs were reviewed between \u003Cstrong>(b)(4)\u003C\u002Fstrong> through \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>This is a repeat deviation from the previous FDA inspection conducted on September 18, 2023 through September 27, 2023 which was discussed relating to the failure to consistently review your monitoring records.\u003C\u002Fp>\u003Cp>Your September 17, 2025 response states the root cause for the lack of monitoring and review of the preventive controls was “\u003Cstrong>(b)(4)\u003C\u002Fstrong>” with the corrective action of “…\u003Cstrong>(b)(4)\u003C\u002Fstrong>…”. Your response lacks evidence to demonstrate that the preventive controls are being adequately implemented, and the management components are being reviewed by \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>3. For your RTE cheese products, your written recall plan does not describe the steps to be taken to directly notify the direct consignees of the food being recalled, including how to return or dispose of the affected food, or to notify the public about any hazard presented by the food when appropriate to protect public health, as required by 21 CFR 117.139(b). Furthermore, there are no assigned responsibilities for the individuals listed as part of the recall team to perform the above-mentioned actions. Your RTE cheese products have multiple known or reasonably foreseeable hazards requiring preventive controls (see 21 CFR § 117.139(a). On July 21, 2025, your facility initiated a recall of multiple cheese products due to positive results for \u003Cem>L. monocytogenes\u003C\u002Fem> in a sample of \u003Cstrong>(b)(4)\u003C\u002Fstrong> cheese product which your facility collected. On August 27, 2025, your facility initiated a second recall due to additional cheese samples testing positive for \u003Cem>L. monocytogenes\u003C\u002Fem> which your facility also collected.\u003C\u002Fp>\u003Cp>This is a repeat deviation from the previous FDA inspection conducted on September 18, 2023, through September 27, 2023 which was discussed relating to your recall plan lacking steps to notify consignees of a recall and assigning responsibilities for such steps.\u003C\u002Fp>\u003Cp>Your September 17, 2025 response identifies the root cause for the inadequate recall plan as “…\u003Cstrong>(b)(4)\u003C\u002Fstrong>” with a resolution of “\u003Cstrong>(b)(4)\u003C\u002Fstrong>.” However, this response is not complete because it does not include a recall plan with updated procedures and assigned responsibilities for those implementing them.\u003C\u002Fp>\u003Cp>\u003Cstrong>\u003Cu>Current Good Manufacturing Practice Requirements (21 CFR Part 117, Subpart B)\u003C\u002Fu>\u003C\u002Fstrong>\u003C\u002Fp>\u003Cp>4. You did not take effective measures to exclude pests from the manufacturing, processing, packing, and holding areas and to protect against the contamination of food on the premises by pests, as required by 21 CFR 117.35(c).\u003C\u002Fp>\u003Cp>Specifically, on August 12, 2025, an FDA Investigator observed one live apparent cockroach on the end of a \u003Cstrong>(b)(4)\u003C\u002Fstrong> table. On August 28, 2025, they observed two live apparent cockroaches in electrical boxes on the wall next to the pasteurizer, three apparent live cockroaches under the edge of the \u003Cstrong>(b)(4)\u003C\u002Fstrong>, one dead apparent cockroach on the floor next to \u003Cstrong>(b)(4)\u003C\u002Fstrong> vat \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and one live apparent cockroach on its back in the bottom of \u003Cstrong>(b)(4)\u003C\u002Fstrong> vat \u003Cstrong>(b)(4)\u003C\u002Fstrong>, which is a food contact surface. On August 13, 2025, the investigator observed approximately 12 apparent rodent excreta pellets and ants, too numerous to count, on the floor of the employee break room. Your employee breakroom is approximately \u003Cstrong>(b)(4)\u003C\u002Fstrong> feet down the hall from the \u003Cstrong>(b)(4)\u003C\u002Fstrong> production room and close to product storage cooler \u003Cstrong>(b)(4)\u003C\u002Fstrong>.\u003C\u002Fp>\u003Cp>Your September 17, 2025 response indicates that you \u003Cstrong>(b)(4)\u003C\u002Fstrong>, and states that the \u003Cstrong>(b)(4)\u003C\u002Fstrong> “…has an effective program…”. However, no evidence was provided to demonstrate the effectiveness of your corrective action.\u003C\u002Fp>\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\u003C\u002Fp>\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\u003C\u002Fp>\u003Cp>Please notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\u003Cp>Please send your reply to the Food and Drug Administration, Attention: Daniel Johnson, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Daniel Johnson via email at: Daniel.Johnson@fda.hhs.gov Please include reference CMS #719761 on any submissions and within the subject line of any email correspondence to the agency.\u003C\u002Fp>\u003Cp>Sincerely,\u003Cbr>\u002FS\u002F\u003C\u002Fp>\u003Cp>Maria S. Knirk, JD, MBA\u003Cbr>Acting Director\u003Cbr>Office of Enforcement\u003Cbr>Office of Compliance and Enforcement\u003Cbr>Human Foods Program\u003C\u002Fp>\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA Electronic Mail\n\nProduct:\n\nFood & Beverages\n\nRecipient:\n\nRecipient Name\n\nMr. Nevin R. Byler\n\nRecipient Title\n\nManager\n\nMiddlefield Original Cheese Cooperative\n\n16942 Kinsman Rd\n\nMiddlefield, OH 44062\n\nUnited States\n\nSunrisecreamery@plainconnect.com\n\nIssuing Office:\n\nHuman Foods Program\n\nUnited States\n\nMarch 6, 2026\nWARNING LETTER\nRe: CMS # 719761\nDear Mr. Byler:\nThe United States Food and Drug Administration (FDA) inspected your ready-to-eat (RTE) human food manufacturing facility, located at 16942 Kinsman Rd Middlefield, OH 44062 on August 12, 2025, through September 8, 2025. This inspection was initiated as a follow-up to a voluntary recall your firm conducted of cheese products due to your findings of pathogenic Listeria monocytogenes (L. monocytogenes) in cheese manufactured by your facility.\nDuring the inspection of your facility, FDA investigators found serious violations of the Current Good Manufacturing Practice, Hazard Analysis, and Risk-Based Preventive Controls for Human Food Regulations (CGMP & PC rule), Title 21, Code of Federal Regulations, Part 117 (21 CFR Part 117). Additionally, FDA collected environmental samples (i.e., swabs) from various areas in your processing facility. FDA laboratory analyses of the environmental swabs found the presences of L. monocytogenes, a human pathogen, in your facility.\nBased on FDA’s inspectional findings and analytical results for samples collected from your production environment, we have determined that the RTE cheese products manufactured in your facility are adulterated within the meaning section 402(a)(4) of the Federal Food, Drug, and Cosmetic Act (the Act) [21 U.S.C. § 342(a)(4)] in that they were prepared, packed, or held under insanitary conditions whereby they may have become contaminated with filth, or whereby they may have been rendered injurious to health. In addition, failure of the owner, operator, or agent in charge of a covered facility to comply with the preventive controls provisions of the CGMP & PC rule (located in Subparts A, C, D, E, F, and G of Part 117) is prohibited by section 301(uu) of the Act [21 U.S.C. § 331(uu)]. You may find the Act and FDA’s regulations through links on FDA’s homepage at www.fda.gov.\nAt the conclusion of the inspection, FDA issued an FDA Form 483 (FDA-483), Inspectional Observations, listing deviations found at your facility. On September 17, 2025, we received your firm’s responses to the FDA-483 via email, describing corrective actions taken and planned by your firm. Based on our review of the inspectional findings and the responses that you provided, we are issuing this letter to advise you of FDA’s continuing concerns and to provide detailed information describing the findings at your facility.\nWe discuss your responses below.\nHazard Analysis and Risk-Based Preventive Controls Requirements (21 CFR Part 117, Subpart C)\n1. You did not implement preventive controls in your food safety plan to provide assurances that any hazards requiring a preventive control will be significantly minimized or prevented and the food manufactured, processed, packed, or held by your facility will not be adulterated under section 402 of the Act, as required by 21 CFR 117.135(a)(1).\nSpecifically, your hazard analysis for your various cheese products identifies the hazard of contamination with environmental pathogens such as “Bacterial Pathogens” such as Listeria, (b)(4). Salmonella, (b)(4), and\u002For (b)(4) as requiring a preventive control at the “(b)(4)” and the “(b)(4)” steps. Your sanitation preventive controls indicate that environmental monitoring is to be performed (b)(4), sanitizer chemical concentrations are to be tested (b)(4), and (b)(4) inspections are to be performed (b)(4). However, FDA Investigators observed the following instances in which you failed to implement your procedures:\na. A review of your records revealed that you had not conducted environmental monitoring during the (b)(4) of (b)(4). This is a repeat deviation from the previous FDA inspection conducted on September 18, 2023 through September 27, 2023 during which it was observed you did not implement (b)(4) environmental monitoring activities as required by your environmental monitoring program.\nb. A review of your records revealed that you failed to test the concentration of your (b)(4) sanitizer during the (b)(4). This (b)(4) sanitizer is used (b)(4) to sanitize your cheese processing equipment (b)(4).\nFurthermore, preventive controls are subject to preventive control management components (monitoring, corrective actions and corrections, and verification) as appropriate to ensure the effectiveness of the preventive controls, taking into account the nature of the preventive control and its role in the facility’s food safety system (see 21 CFR 117.140). We note that you did not have adequate controls in place for contamination with environmental pathogens regarding monitoring, corrective action and verification activities, as evidenced by the following observations during the inspection:\nc. A review of your environmental monitoring records revealed positive findings of L. monocytogenes in your facility on (b)(4) and again in repeat locations beginning on (b)(4) through (b)(4). The repeat positive findings collected from the same locations indicate that your current corrective action strategy of cleaning, sanitizing, and re-swabbing until achieving negative results is inadequate for controlling environmental pathogens in your facility.\nd. FDA Investigators collected an environmental sample from your facility on August 12, 2025 during the manufacturing of (b)(4) cheese. The sample consisted of 80 environmental swabs collected from various surfaces in your (b)(4) room, which resulted in the finding of 14 positive swabs for L. monocytogenes.\ne. Your written environmental monitoring program, dated January 9, 2023, specifies the “corrective action for environmental monitoring positive listeria” for “Zone (b)(4)” is to “…Clean equipment and resample for Listeria…”, “…Reclean and resample until negative sample” and “Conduct retraining for employee Sanitation.” However, your environmental monitoring program is inadequate because it does not include a procedure for determining the root cause of contamination and does not address product disposition after a positive result is reported, as required by 21 CFR 117.150(a)(2).\nf. The FDA investigators observed equipment in your (b)(4) room which lacked an adequately cleanable design which creates a food contamination risk. Specifically, the metal surfaces surrounding the underside of the (b)(4) were corroded and pieces of metal flaked off upon touching the surface.\nYour September 17, 2025 response identified the root cause of the L. monocytogenes finding in the plant as “…(b)(4)…” and “…(b)(4)…” and states that you took the corrective actions of (b)(4). However, your response does not identify the source of the L. monocytogenes or include any evidence that an investigation was conducted to determine the source of contamination. Your response also does not include evidence to demonstrate that the referenced actions have been completed such as the updated environmental monitoring program, cleaning\u002Fsanitation procedures, corresponding monitoring records, and photographic evidence or a detailed description of what was cleaned and sanitized and how the tasks were completed to demonstrate the facility and equipment repairs were made. Furthermore, your response included a laboratory report, dated (b)(4), capturing environmental monitoring results for (b)(4) swab sub-samples collected on (b)(4). One collection of (b)(4) environmental swabs is not representative of a (b)(4) square foot facility as it does not provide adequate assurance that the L. monocytogenes found in your facility has been eliminated from the processing environment based on the severity of the findings in the environment and in finished product.\n2. You did not review your process preventive control monitoring and verification records, as required by 21 CFR 117.165(a)(4).\nSpecifically:\na. From January 2025 through July 2025, your (b)(4) sanitation forms for the (b)(4) production room, plant packaging area, and (b)(4) room repeatedly lacked a signature, or included a signature with no date, to indicate who reviewed the records and when.\nb. From (b)(4) through (b)(4) your (b)(4) cleaning log lacked dates for record review.\nc. From April 2025 through August 2025, your (b)(4) “chemical concentration logs” lacked signatures capturing review. Your chemical concentration logs capture concentrations for detergents and sanitizers used for cleaning and sanitizing the manufacturing environment and equipment.\nd. Your (b)(4) test results for January 2, 2025, through August 19, 2025, lacked signatures or dates to indicate the results were reviewed. Your (b)(4) records capture the testing for the presence of antibiotic residues for your incoming raw milk.\ne. Your (b)(4) pasteurizer time and temperature monitoring charts contained review signatures but lacked review dates for charts dated (b)(4) and (b)(4) and (b)(4).\nf. Your metal detector verification log lacked signatures or dates to indicate the logs were reviewed between (b)(4) through (b)(4).\nThis is a repeat deviation from the previous FDA inspection conducted on September 18, 2023 through September 27, 2023 which was discussed relating to the failure to consistently review your monitoring records.\nYour September 17, 2025 response states the root cause for the lack of monitoring and review of the preventive controls was “(b)(4)” with the corrective action of “…(b)(4)…”. Your response lacks evidence to demonstrate that the preventive controls are being adequately implemented, and the management components are being reviewed by (b)(4).\n3. For your RTE cheese products, your written recall plan does not describe the steps to be taken to directly notify the direct consignees of the food being recalled, including how to return or dispose of the affected food, or to notify the public about any hazard presented by the food when appropriate to protect public health, as required by 21 CFR 117.139(b). Furthermore, there are no assigned responsibilities for the individuals listed as part of the recall team to perform the above-mentioned actions. Your RTE cheese products have multiple known or reasonably foreseeable hazards requiring preventive controls (see 21 CFR § 117.139(a). On July 21, 2025, your facility initiated a recall of multiple cheese products due to positive results for L. monocytogenes in a sample of (b)(4) cheese product which your facility collected. On August 27, 2025, your facility initiated a second recall due to additional cheese samples testing positive for L. monocytogenes which your facility also collected.\nThis is a repeat deviation from the previous FDA inspection conducted on September 18, 2023, through September 27, 2023 which was discussed relating to your recall plan lacking steps to notify consignees of a recall and assigning responsibilities for such steps.\nYour September 17, 2025 response identifies the root cause for the inadequate recall plan as “…(b)(4)” with a resolution of “(b)(4).” However, this response is not complete because it does not include a recall plan with updated procedures and assigned responsibilities for those implementing them.\nCurrent Good Manufacturing Practice Requirements (21 CFR Part 117, Subpart B)\n4. You did not take effective measures to exclude pests from the manufacturing, processing, packing, and holding areas and to protect against the contamination of food on the premises by pests, as required by 21 CFR 117.35(c).\nSpecifically, on August 12, 2025, an FDA Investigator observed one live apparent cockroach on the end of a (b)(4) table. On August 28, 2025, they observed two live apparent cockroaches in electrical boxes on the wall next to the pasteurizer, three apparent live cockroaches under the edge of the (b)(4), one dead apparent cockroach on the floor next to (b)(4) vat (b)(4), and one live apparent cockroach on its back in the bottom of (b)(4) vat (b)(4), which is a food contact surface. On August 13, 2025, the investigator observed approximately 12 apparent rodent excreta pellets and ants, too numerous to count, on the floor of the employee break room. Your employee breakroom is approximately (b)(4) feet down the hall from the (b)(4) production room and close to product storage cooler (b)(4).\nYour September 17, 2025 response indicates that you (b)(4), and states that the (b)(4) “…has an effective program…”. However, no evidence was provided to demonstrate the effectiveness of your corrective action.\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your products. You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law, including FDA regulations.\nThis letter notifies you of our concerns and provides you an opportunity to address them. You should take prompt action to correct any violations. Failure to adequately address these violations may result in legal action without further notice, including, without limitation, seizure, injunction, or administrative action for suspension of food facility registration if criteria and conditions warrant.\nPlease notify FDA in writing, within 15 working days of receipt of this letter, of the specific steps you have taken to address any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within 15 working days, state the reason for the delay and the time within which you will do so. If you believe that your products are not in violation of the Act, include your reasoning and any supporting information for our consideration.\nPlease send your reply to the Food and Drug Administration, Attention: Daniel Johnson, Compliance Officer, Human Foods Program – Office of Compliance and Enforcement, Office of Enforcement – Division of Conventional Foods Enforcement (HFS-607), 5001 Campus Drive, College Park, MD 20740 U.S.A. If you have any questions regarding any issues in this letter, please contact Daniel Johnson via email at: Daniel.Johnson@fda.hhs.gov Please include reference CMS #719761 on any submissions and within the subject line of any email correspondence to the agency.\nSincerely,\n\u002FS\u002F\nMaria S. Knirk, JD, MBA\nActing Director\nOffice of Enforcement\nOffice of Compliance and Enforcement\nHuman Foods Program","Middlefield Original Cheese Cooperative","middlefield-original-cheese-cooperative-719761-03062026","2026-10-14T12:31:16.41489+00:00","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fmiddlefield-original-cheese-cooperative-719761-03062026","2026-11-10T01:02:16.121874+00:00","2026-09-29","719761","Mr. Nevin R. Byler","2026-10-14T12:35:12.707+00:00","VIA Electronic Mail","2026-03-06",{"id":221,"raw":222,"subject":227,"body_html":228,"body_text":229,"firm_name":230,"letter_id":231,"created_at":76,"fei_number":19,"letter_url":232,"updated_at":233,"action_type":22,"case_status":23,"posted_date":234,"marcs_cms_no":235,"product_type":236,"closeout_date":19,"issuing_office":226,"recipient_name":237,"body_fetched_at":238,"delivery_method":152,"recipient_title":19,"reference_number":19,"action_taken_date":239,"medical_device_id":19,"response_letter_date":19},3036,[223,224,225,226,227,13,13,13],"\u003Ctime datetime=\"2021-11-09T14:20:00Z\">11\u002F09\u002F2021\u003C\u002Ftime>\n","\u003Ctime datetime=\"2021-10-20T04:00:00Z\">10\u002F20\u002F2021\u003C\u002Ftime>\n","\u003Ca href=\"\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbartlett-cooperative-association-bartlett-feed-mill-614832-10202021\">Bartlett Cooperative Association Bartlett Feed Mill\u003C\u002Fa>","Office of Human and Animal Foods West Division II","CGMP\u002FMedicated Feeds\u002FAdulterated","\n\n                            \n                            \n                            \n                            \n                                              \n  \n \n\n                 \n\n  \u003Chr>\n \n\n\u003Cdiv>\n  \u003Cdl>\n\n              \u003Cdt>Delivery Method:\u003C\u002Fdt> \n        \u003Cdd>VIA UNITED PARCEL SERVICE\n                                                                                                                                                                                                                                                                                                                                                                                                                              \u003C\u002Fdd>\n      \n      \n              \u003Cdt>Product:\u003C\u002Fdt> \n        \u003Cdd>Animal &amp; Veterinary\u003Cbr>Drugs                          \n            \n            \n            \n            \n            \n            \n            \n             \n            \n            \n            \n              \n            \n            \n            \u003C\u002Fdd>\n      \n          \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n\n\u003Chr>\n\n\u003Cdiv>\n  \u003Cdiv>\n    \u003Cdl>\n\n        \u003Cdt>Recipient:\u003C\u002Fdt>\n\n                      \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Name\u003C\u002Fdiv>\n              \u003Cdiv>Samuel Perry Sorrell\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n                                \u003Cdd>\n  \u003Cdiv>\n    \u003Cdiv>Recipient Title\u003C\u002Fdiv>\n              \u003Cdiv>General Manager\u003C\u002Fdiv>\n          \u003C\u002Fdiv>\n\u003C\u002Fdd>\n          \n            \u003Cdd>Bartlett Cooperative Association Bartlett Feed Mill\u003C\u002Fdd>\n\n          \n                      \u003Cdd>\u003Cp>\u003Cspan>401 Main St Ste A\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>Bartlett\u003C\u002Fspan>, \u003Cspan>KS\u003C\u002Fspan> \u003Cspan>67332-3205\u003C\u002Fspan>\u003Cbr>\n\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n          \n          \n          \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>            \n\n       \u003Cdiv>\n    \u003Cdl>\n          \n          \u003Cdt>Issuing Office:\u003C\u002Fdt>\n        \n         \n          \u003Cdd>Office of Human and Animal Foods West Division II\u003C\u002Fdd>\n        \n         \n          \u003Cdd>\u003Cp>\u003Cspan>United States\u003C\u002Fspan>\u003C\u002Fp>\u003C\u002Fdd>\n        \n        \n        \n        \n        \n    \u003C\u002Fdl>\n    \u003Cdl> \n      \n    \u003C\u002Fdl>\n  \u003C\u002Fdiv>  \n      \n\u003C\u002Fdiv>\n\n \n\n \n\n\u003Chr>\n\n\u003Cp>October 20, 2021\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>WARNING LETTER\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>CMS # 614832\u003C\u002Fp>\n\n\u003Cp>Dear Mr. Sorrell,\u003C\u002Fp>\n\n\u003Cp>The U.S. Food and Drug Administration (FDA) conducted an inspection of your animal feed manufacturing facility located at 401 Main St., Suite A, Bartlett, Kansas on March 11, 2021, March 22, 2021, and March 24, 2021. The inspection was initiated as a follow-up to a Class I voluntary recall of a custom formulated cattle feed that was reported to have contributed to the death of approximately eighty-seven (87) cattle upon its consumption.\u003C\u002Fp>\n\n\u003Cp>The inspection revealed evidence of a significant violation of the Current Good Manufacturing Practice (CGMP) regulations for non-licensed medicated animal feed manufacturers, Title 21, Code of Federal Regulations, Part 225 (21 CFR Part 225). Failure to follow these requirements causes medicated feeds and non-medicated animal foods manufactured at your facility to be adulterated under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&amp;C Act) [21 U.S.C. § 351(a)(2)(B)] and Section 402(a)(2)(C)(ii) of the FD&amp;C Act [21 U.S.C. § 342(a)(2)(C)(ii)] (see 21 CFR 225.1(b)(1)).\u003C\u002Fp>\n\n\u003Cp>In addition, the inspection revealed evidence that you manufactured and distributed a cattle feed that contained a super-potent concentration of the new animal drug monensin. This Type C medicated cattle feed containing the Type A medicated article of monensin is unsafe within the meaning of Section 512(a)(2)(A) of the FD&amp;C Act [21 U.S.C. § 360b(a)(2)(A)] because it was not in conformance with the animal drug approval. As a result, the animal feed containing the new animal drug is adulterated under Section 501(a)(6) of the FD&amp;C Act [21 U.S.C. § 351(a)(6)].\u003C\u002Fp>\n\n\u003Cp>Finally, the inspection found evidence that this custom cattle feed is also misbranded within the meaning of Section 502(a)(1) of the FD&amp;C Act [21 U.S.C. § 352(a)(1)] because it contained monensin at a concentration above the level stated in the product labeling (feeding directions accompanying the feed), making the labeling false or misleading.\u003C\u002Fp>\n\n\u003Cp>The introduction or delivery for introduction into interstate commerce of any food that is adulterated or misbranded is a prohibited act within the meaning of Section 301(a) of the FD&amp;C Act [21 U.S.C. § 331(a)]. You may find FDA’s regulations and the FD&amp;C Act through links on FDA’s homepage at \u003Ca href=\"http:\u002F\u002Fwww.fda.gov.\u002F\">http:\u002F\u002Fwww.fda.gov.\u003C\u002Fa>\u003C\u002Fp>\n\n\u003Cp>At the close of the inspection, you were issued a Form FDA 483, Inspectional Observations. On April 27, 2021, you were issued an amended Form FDA 483. We acknowledge your written response dated May 12, 2021. We have reviewed your response and address your corrective actions below.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Current Good Manufacturing Practice (CGMP) Requirements For Medicated Feeds\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>As a non-licensed, medicated feed mill, your facility is subject to the medicated feed CGMP regulations for non-licensed, medicated animal feed manufacturers found in 21 CFR 225.120-225.202. During the inspection of your facility, an FDA Investigator observed evidence of significant violations of these requirements as indicated by the following:\u003C\u002Fp>\n\n\u003Cp>1. You failed to ensure that the amount of the Type A medicated article of monensin added during the production of a Type C medicated feed for growing beef cattle on pasture or in a dry lot (stocker and feeder cattle and dairy and beef replacement heifers) was in accordance with the monensin’s labeled mixing directions as required by 21 CFR 225.142.\u003C\u002Fp>\n\n\u003Cp>Specifically, your facility manufactured a custom formulated Type C medicated cattle feed between \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;and \u003Cstrong>(b)(4)\u003C\u002Fstrong>&nbsp;that contained a super-potent concentration of monensin. On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, your facility received order number 483855 for 6 tons of medicated feed containing monensin. One of your employees created the formulation for order number 483855 to include 40.5 pounds (lbs) of Rumensin 90G in an approximate 6-ton lot (612 g\u002Fton of monensin). On \u003Cstrong>(b)(4)\u003C\u002Fstrong>, due to a mix-up at the \u003Cstrong>(b)(4)\u003C\u002Fstrong> station, an employee changed the order number to 483857 and manufactured an approximate 8-ton lot with 54.3 lbs of \u003Cstrong>(b)(4)\u003C\u002Fstrong>, as a substitute for Rumensin 90G (616 g\u002Fton of monensin). The maximum approved concentration of monensin in a cattle feed labeled for growing beef cattle on pasture or in a dry lot (stocker and feeder cattle and dairy and beef replacement heifers) for increased rate of weight gain is 400 g\u002Fton as defined by\u003Cbr>\n21 CFR 558.355(f)(3)(vi).\u003C\u002Fp>\n\n\u003Cp>The super-potent cattle feed distributed under order number 483857 was reported to have contributed to the deaths of approximately eighty-seven (87) growing cattle following its consumption.\u003C\u002Fp>\n\n\u003Cp>2. You failed to ensure that all deliveries of medicated feeds, whether bagged or in bulk, are adequately labeled to assure that the feed can be properly used as required by 21 CFR 225.180.\u003C\u002Fp>\n\n\u003Cp>Specifically, on or after February 18, 2021, you distributed a Type C medicated feed under order number 483857 for growing beef cattle on pasture or in a dry lot (stocker and feeder cattle and dairy and beef replacement heifers) for increased rate of weight gain. The labeling provided with the delivery has feeding directions that state, “Feed 2.3 to 8.8 lbs\u002Fhead\u002Fday to provide at a rate of 50 to 200 milligrams\u002Fhead\u002Fday in not less than 1 pound of feed or, after the 5th day, feed at a rate of 400 milligrams\u002Fhead\u002Fday every other day in not less than 2 pounds of feed.” However, this custom formulated Type C medicated feed contained monensin at a concentration of approximately 616 grams\u002Fton. Therefore, when fed at a rate of 2.3 to 8.8 lbs\u002Fhead\u002Fday, it would provide monensin at a rate of approximately 708 to 2,710 milligrams (mg)\u002Fhead\u002Fday.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Misbranded Animal Food\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>During the inspection of your facility, an FDA Investigator reviewed the animal feed labeling for order number 483855\u002F483857 and found evidence that the formulated product was misbranded under Section 502(a)(1) of the FD&amp;C Act [21 U.S.C. § 352(a)(1)] because the labeling was false or misleading.\u003C\u002Fp>\n\n\u003Cp>Specifically, order number 483855\u002F483857 was custom formulated to contain monensin at a concentration of approximately 616 grams\u002Fton. However, the labeling accompanying the animal feed stated that the monensin concentration was 45 grams\u002Fton. Additionally, the feeding directions in the labeling state, “Feed 2.3 to 8.8 lbs\u002Fhead\u002Fday to provide at a rate of 50 to 200 milligrams\u002Fhead\u002Fday in not less than 1 pound of feed or, after the 5th day, feed at a rate of 400 milligrams\u002Fhead\u002Fday every other day in not less than 2 pounds of feed,” which is inconsistent with the formulated concentration level. The manufactured feed containing approximately 616 grams\u002Fton would provide approximately 308 mg\u002Flb. This feed, when fed at a rate of 2.3 to 8.8 lbs\u002Fhead\u002Fday, would provide monensin at a rate of approximately 708 to 2,710 mg\u002Fhead\u002Fday, which is approximately 3.5 to 13.5 times the maximum labeled daily intake of 200 mg\u002Fhead\u002Fday (or 400 mg\u002Fhead every other day).\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Corrective Actions\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>We have reviewed your May 12, 2021 response to the Form FDA 483 (Inspectional Observations). You reported that you have taken measures to educate employees on how to:\u003C\u002Fp>\n\n\u003Cp> place a label with the product and keep such label with the product until such time the product has been included in the feed ration,\u003Cbr>\n properly formulate feed rations,\u003Cbr>\n calculate the inclusion rate in the finished feed,\u003Cbr>\n ensure the inclusion rate, as well as the rate stated in the feeding directions, is in the approved range for the intended class of animal that is being fed,\u003Cbr>\n ensure the correct amount of medicated article and \u003Cstrong>(b)(4)\u003C\u002Fstrong> included in a feed ration are weighed correctly, and\u003Cbr>\n notify the office prior to delivery if the inclusion rate of a medicated article deviates from the stated value on the feed run sheet so that the feeding direction sheet can be corrected and checked to ensure the inclusion rate is in the approved range for the intended species.\u003C\u002Fp>\n\n\u003Cp>However, we are unable to fully evaluate your corrective actions since you did not provide supporting documentation to demonstrate the promised corrections have been completed or implemented. We encourage you to submit supporting documentation related to your corrective actions in your reply.\u003C\u002Fp>\n\n\u003Cp>\u003Cstrong>Conclusion\u003C\u002Fstrong>\u003C\u002Fp>\n\n\u003Cp>This letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\u003C\u002Fp>\n\n\u003Cp>This letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\u003C\u002Fp>\n\n\u003Cp>Within fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&amp;C Act, include your reasoning and any supporting information for our consideration.\u003C\u002Fp>\n\n\u003Cp>Please send your firm’s response to Danial S. Hutchison, Compliance Officer, U.S. Food and Drug Administration, 8050 Marshall Dr., Suite 205, Lenexa, KS 66214. If you have any questions about this letter, please contact Compliance Officer Hutchison at 913-495-5154.\u003C\u002Fp>\n\n\u003Cp>Sincerely,\u003Cbr>\n\u002FS\u002F\u003C\u002Fp>\n\n\u003Cp>LaTonya M. Mitchell, Ph.D.\u003Cbr>\nProgram Division Director\u003Cbr>\nOffice of Human and Animal Foods\u003Cbr>\nWest Division II\u003C\u002Fp>\n\n\n\n\n\n\n\n              \n                                            \n              \n            ","Delivery Method:\n\nVIA UNITED PARCEL SERVICE\n\nProduct:\n\nAnimal & Veterinary\nDrugs\n\nRecipient:\n\nRecipient Name\n\nSamuel Perry Sorrell\n\nRecipient Title\n\nGeneral Manager\n\nBartlett Cooperative Association Bartlett Feed Mill\n\n401 Main St Ste A\n\nBartlett, KS 67332-3205\n\nUnited States\n\nIssuing Office:\n\nOffice of Human and Animal Foods West Division II\n\nUnited States\n\nOctober 20, 2021\n\nWARNING LETTER\n\nCMS # 614832\n\nDear Mr. Sorrell,\n\nThe U.S. Food and Drug Administration (FDA) conducted an inspection of your animal feed manufacturing facility located at 401 Main St., Suite A, Bartlett, Kansas on March 11, 2021, March 22, 2021, and March 24, 2021. The inspection was initiated as a follow-up to a Class I voluntary recall of a custom formulated cattle feed that was reported to have contributed to the death of approximately eighty-seven (87) cattle upon its consumption.\n\nThe inspection revealed evidence of a significant violation of the Current Good Manufacturing Practice (CGMP) regulations for non-licensed medicated animal feed manufacturers, Title 21, Code of Federal Regulations, Part 225 (21 CFR Part 225). Failure to follow these requirements causes medicated feeds and non-medicated animal foods manufactured at your facility to be adulterated under Section 501(a)(2)(B) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) [21 U.S.C. § 351(a)(2)(B)] and Section 402(a)(2)(C)(ii) of the FD&C Act [21 U.S.C. § 342(a)(2)(C)(ii)] (see 21 CFR 225.1(b)(1)).\n\nIn addition, the inspection revealed evidence that you manufactured and distributed a cattle feed that contained a super-potent concentration of the new animal drug monensin. This Type C medicated cattle feed containing the Type A medicated article of monensin is unsafe within the meaning of Section 512(a)(2)(A) of the FD&C Act [21 U.S.C. § 360b(a)(2)(A)] because it was not in conformance with the animal drug approval. As a result, the animal feed containing the new animal drug is adulterated under Section 501(a)(6) of the FD&C Act [21 U.S.C. § 351(a)(6)].\n\nFinally, the inspection found evidence that this custom cattle feed is also misbranded within the meaning of Section 502(a)(1) of the FD&C Act [21 U.S.C. § 352(a)(1)] because it contained monensin at a concentration above the level stated in the product labeling (feeding directions accompanying the feed), making the labeling false or misleading.\n\nThe introduction or delivery for introduction into interstate commerce of any food that is adulterated or misbranded is a prohibited act within the meaning of Section 301(a) of the FD&C Act [21 U.S.C. § 331(a)]. You may find FDA’s regulations and the FD&C Act through links on FDA’s homepage at http:\u002F\u002Fwww.fda.gov.\n\nAt the close of the inspection, you were issued a Form FDA 483, Inspectional Observations. On April 27, 2021, you were issued an amended Form FDA 483. We acknowledge your written response dated May 12, 2021. We have reviewed your response and address your corrective actions below.\n\nCurrent Good Manufacturing Practice (CGMP) Requirements For Medicated Feeds\n\nAs a non-licensed, medicated feed mill, your facility is subject to the medicated feed CGMP regulations for non-licensed, medicated animal feed manufacturers found in 21 CFR 225.120-225.202. During the inspection of your facility, an FDA Investigator observed evidence of significant violations of these requirements as indicated by the following:\n\n1. You failed to ensure that the amount of the Type A medicated article of monensin added during the production of a Type C medicated feed for growing beef cattle on pasture or in a dry lot (stocker and feeder cattle and dairy and beef replacement heifers) was in accordance with the monensin’s labeled mixing directions as required by 21 CFR 225.142.\n\nSpecifically, your facility manufactured a custom formulated Type C medicated cattle feed between (b)(4) and (b)(4) that contained a super-potent concentration of monensin. On (b)(4), your facility received order number 483855 for 6 tons of medicated feed containing monensin. One of your employees created the formulation for order number 483855 to include 40.5 pounds (lbs) of Rumensin 90G in an approximate 6-ton lot (612 g\u002Fton of monensin). On (b)(4), due to a mix-up at the (b)(4) station, an employee changed the order number to 483857 and manufactured an approximate 8-ton lot with 54.3 lbs of (b)(4), as a substitute for Rumensin 90G (616 g\u002Fton of monensin). The maximum approved concentration of monensin in a cattle feed labeled for growing beef cattle on pasture or in a dry lot (stocker and feeder cattle and dairy and beef replacement heifers) for increased rate of weight gain is 400 g\u002Fton as defined by\n\n21 CFR 558.355(f)(3)(vi).\n\nThe super-potent cattle feed distributed under order number 483857 was reported to have contributed to the deaths of approximately eighty-seven (87) growing cattle following its consumption.\n\n2. You failed to ensure that all deliveries of medicated feeds, whether bagged or in bulk, are adequately labeled to assure that the feed can be properly used as required by 21 CFR 225.180.\n\nSpecifically, on or after February 18, 2021, you distributed a Type C medicated feed under order number 483857 for growing beef cattle on pasture or in a dry lot (stocker and feeder cattle and dairy and beef replacement heifers) for increased rate of weight gain. The labeling provided with the delivery has feeding directions that state, “Feed 2.3 to 8.8 lbs\u002Fhead\u002Fday to provide at a rate of 50 to 200 milligrams\u002Fhead\u002Fday in not less than 1 pound of feed or, after the 5th day, feed at a rate of 400 milligrams\u002Fhead\u002Fday every other day in not less than 2 pounds of feed.” However, this custom formulated Type C medicated feed contained monensin at a concentration of approximately 616 grams\u002Fton. Therefore, when fed at a rate of 2.3 to 8.8 lbs\u002Fhead\u002Fday, it would provide monensin at a rate of approximately 708 to 2,710 milligrams (mg)\u002Fhead\u002Fday.\n\nMisbranded Animal Food\n\nDuring the inspection of your facility, an FDA Investigator reviewed the animal feed labeling for order number 483855\u002F483857 and found evidence that the formulated product was misbranded under Section 502(a)(1) of the FD&C Act [21 U.S.C. § 352(a)(1)] because the labeling was false or misleading.\n\nSpecifically, order number 483855\u002F483857 was custom formulated to contain monensin at a concentration of approximately 616 grams\u002Fton. However, the labeling accompanying the animal feed stated that the monensin concentration was 45 grams\u002Fton. Additionally, the feeding directions in the labeling state, “Feed 2.3 to 8.8 lbs\u002Fhead\u002Fday to provide at a rate of 50 to 200 milligrams\u002Fhead\u002Fday in not less than 1 pound of feed or, after the 5th day, feed at a rate of 400 milligrams\u002Fhead\u002Fday every other day in not less than 2 pounds of feed,” which is inconsistent with the formulated concentration level. The manufactured feed containing approximately 616 grams\u002Fton would provide approximately 308 mg\u002Flb. This feed, when fed at a rate of 2.3 to 8.8 lbs\u002Fhead\u002Fday, would provide monensin at a rate of approximately 708 to 2,710 mg\u002Fhead\u002Fday, which is approximately 3.5 to 13.5 times the maximum labeled daily intake of 200 mg\u002Fhead\u002Fday (or 400 mg\u002Fhead every other day).\n\nCorrective Actions\n\nWe have reviewed your May 12, 2021 response to the Form FDA 483 (Inspectional Observations). You reported that you have taken measures to educate employees on how to:\n\n place a label with the product and keep such label with the product until such time the product has been included in the feed ration,\n\n properly formulate feed rations,\n\n calculate the inclusion rate in the finished feed,\n\n ensure the inclusion rate, as well as the rate stated in the feeding directions, is in the approved range for the intended class of animal that is being fed,\n\n ensure the correct amount of medicated article and (b)(4) included in a feed ration are weighed correctly, and\n\n notify the office prior to delivery if the inclusion rate of a medicated article deviates from the stated value on the feed run sheet so that the feeding direction sheet can be corrected and checked to ensure the inclusion rate is in the approved range for the intended species.\n\nHowever, we are unable to fully evaluate your corrective actions since you did not provide supporting documentation to demonstrate the promised corrections have been completed or implemented. We encourage you to submit supporting documentation related to your corrective actions in your reply.\n\nConclusion\n\nThis letter is not intended to be an all-inclusive statement of violations that may exist at your facility or in connection with your product(s). You are responsible for investigating and determining the causes of any violations and for preventing their recurrence or the occurrence of other violations. It is your responsibility to ensure that your firm complies with all requirements of federal law and FDA regulations.\n\nThis letter notifies you of our concerns and provides you an opportunity to address them. Failure to adequately address this matter may lead to legal action, including without limitation, seizure, and injunction.\n\nWithin fifteen (15) working days of receipt of this letter, please notify this office in writing of the specific steps that you have taken to correct any violations. Include an explanation of each step being taken to prevent the recurrence of violations, as well as copies of related documentation. If you cannot complete corrective actions within fifteen (15) working days, state the reason for the delay and the time within which you will complete the correction. If you believe that your products are not in violation of the FD&C Act, include your reasoning and any supporting information for our consideration.\n\nPlease send your firm’s response to Danial S. Hutchison, Compliance Officer, U.S. Food and Drug Administration, 8050 Marshall Dr., Suite 205, Lenexa, KS 66214. If you have any questions about this letter, please contact Compliance Officer Hutchison at 913-495-5154.\n\nSincerely,\n\n\u002FS\u002F\n\nLaTonya M. Mitchell, Ph.D.\n\nProgram Division Director\n\nOffice of Human and Animal Foods\n\nWest Division II","Bartlett Cooperative Association Bartlett Feed Mill","bartlett-cooperative-association-bartlett-feed-mill-614832-10202021","https:\u002F\u002Fwww.fda.gov\u002Finspections-compliance-enforcement-and-criminal-investigations\u002Fwarning-letters\u002Fbartlett-cooperative-association-bartlett-feed-mill-614832-10202021","2026-10-26T08:08:01.611342+00:00","2021-11-09","614832","Animal & VeterinaryDrugs","Samuel Perry Sorrell","2026-08-20T02:27:08.664+00:00","2021-10-20",12,{"510k":242,"classification":243,"enforcement":244,"event":245,"event_backfill":246,"pma":247,"warning_letter":248},"2026-11-16T02:00:55.89+00:00","2026-11-16T02:00:41.999+00:00","2026-11-16T02:00:49.415+00:00","2026-11-16T04:00:38.924+00:00","2026-09-07T05:17:28.839+00:00","2026-11-16T02:01:03.155+00:00","2026-11-17T01:02:55.859+00:00"]